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CHAPTER I 
 
INTRODUCTION 
 
 The Eph family is the largest subfamily of receptor tyrosine kinases, with 14 
members.  Since the first eph gene was cloned in 1987 (1), the Eph family of receptor 
tyrosine kinases (RTK) has been implicated in many physiological and pathological 
processes.  The first Eph receptor identified, EphA1, was found to be expressed in 
erythropoietin producing hepatoma cells (eph).  The Eph family of receptors can be 
divided into two classes, an EphA class and an EphB class based on the sequence 
homology and binding affinity to the ephrin ligands.  There are at least nine EphA 
receptors which generally bind with different affinities to five ephrinA ligands.  There 
are five EphB receptors which interact with three ephrinB ligands.  There are 
exceptions, EphA4 can also interact with ephrinB2 and ephrinB3, and EphB2 can also 
interact with ephrinA5 (Fig 1).  One unique feature of Eph/ephrin signaling is that 
both the receptor and ligand are membrane bound, making it possible to have bi-
directional signaling.  EphrinA proteins are anchored to the plasma membrane 
through glycosylphosphatidylinositol linkage (GPI), while ephrinB proteins contain a 
transmembrane domain and cytoplasmic tail.  When the Eph receptor interacts with 
an ephrin ligand on a neighboring cell, the Eph receptor clusters and trans-
phosphorylates an adjacent Eph receptor to transduce a cellular signal (forward 
signaling).  Eph/ephrin interactions also cause clustering of ephrin ligands on 
neighboring cells to activate reverse signaling [reviewed in(2, 3)]. 
 2
 
 
 
 
 
 
Figure 1.  Eph family of receptor tyrosine kinases and ephrin ligands.  There are nine 
EphA receptors and five EphB receptors.  Generally, EphA receptors interact with 
ephrinA ligands and EphB receptors binds ephrinB ligands.  There are exceptions, as 
EphA4 can bind ephrinB2/3 and EphB2 can bind ephrinA5. 
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 Similar to other RTKs, the Eph receptors contain an extracellular, transmembrane, 
and cytoplasmic domain.  The extracellular portion of the Eph receptor consists of 
three distinct regions:  a ligand binding domain, a cysteine rich region, and 
fibronectin repeats (Fig 2)(4-7).  Interestingly, it has been reported that each of these 
domains is capable of interacting with ephrin ligands.  The ligand binding domain 
binds ephrins with high affinity.  The cysteine rich region can also associate with 
ephrins but with a lower binding affinity, and promotes clustering of the receptor (5, 
8, 9).  The fibronectin repeats have been reported to bind ephrins as well, but only in 
a cis-manner when both the receptor and ligand are on the same cell, and is also 
believed to facilitate receptor clustering.  The cytoplasmic portion of Eph is divided 
into three distinct regions:  juxtamembrane region, the kinase domain, and SAM 
domain (Fig 2) (2, 10).  Phosphorylation of tyrosines within the cytoplasmic region is 
critical in Eph kinase activity and interactions with signaling proteins.  This will be 
discussed further in relation to EphA2 signaling. 
 
EphA2 function in angiogenesis 
 One Eph family member, EphA2, has been shown to be critical in many 
physiological and pathological processes.  EphA2 was identified from a screen of 
epithelial cells for conserved receptor tyrosine kinases in 1990, original termed 
Epithelial Cell Receptor Protein-Tyrosine Kinase (eck) (11).  Since its discovery, 
there has been a wealth of research on EphA2 signaling and its role in development 
and disease. 
 4
 
 
 
 
 
 
Figure 2.  Eph receptor and ephrin ligand structures.  The Eph receptor has three 
conserved extracellular domains:  a globular/ephrin binding domain (G), a cysteine 
rich region (C), and two fibronectin repeats.  The intracellular region of the receptor 
contains a juxtamembrane region, a kinase domain, and a sterile alpha motif (S).  The 
ephrinA ligands are tethered to the membrane by a glycosylphosphatidylinositol 
(GPI) linkage, while ephrinB ligands contain a cytoplasmic tail.  Eph receptors and 
ephrinB ligands contain numerous tyrosines within the cytoplasmic region that serve 
as potential phosphorylation and protein binding sites ( ). 
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 Blood vessel formation is a fundamental process, that is categorized into two 
types:  vasculogenesis and angiogenesis.  Vasculogenesis is the de novo synthesis of 
blood vessels.  The process of vasculogenesis involves differentiation of angioblasts, 
originally derived from mesoderm, into endothelial cells. The endothelial cells 
assemble into a luminal network that undergoes remodeling during vasculogenesis.  
Recruitment of supporting cells such as pericytes and smooth muscle cells forms the 
mature and functional blood vessel (12).  Angiogenesis, by contrast, involves 
sprouting of new blood vessel branches from pre-existing vasculature and this process 
also involves endothelial cell proliferation, migration, tubulogenesis, and recruitment 
of perivascular supporting cells (12, 13).  Several of the Eph receptors are reported to 
be expressed in the vascular system.  EphrinB2 is expressed in arterial endothelial 
cells and EphB4 is expressed almost exclusively on venous endothelial cells (14).  
These were among the first markers to distinguish arteries from veins, but it is unclear 
what the functional relevance is of this arteriovenous-specific expression pattern.  
Targeted disruption of either molecule results in embryonic lethality, at E10.5.  These 
mice exhibit defects in vessel remodeling.   Inactivation of either gene affected 
formation of both arteries and veins (14-16).   EphrinB1 and EphB1 were detected in 
the developing kidney endothelium (17).  Similar to EphB4, EphB3 is predominantly 
expressed in veins (15).  EphB2 expression was detected in embryonic CNS, heart, 
and peripheral nerves (15, 18).  EphrinB2 and EphB2 expression is also found in 
mesenchymal supporting cells (15).  Inactivation of EphB2 or EphB3 alone in mice 
did not reveal any overt phenotype.  In EphB2 /EphB3 double knockout mice, about 
30% of these animals displayed a vessel defect and were embryonic lethal (15).  In 
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situ hybridization of ephrinA1 exhibited expression in mesoderm and pre-endocardial 
cells at E7.25, the dorsal aorta at E8.5, the primary head vein, intersomatic vessels, 
and limb bud vasculature at E9.5 (19).  EphA receptor expression was detected in 
many blood vessels, such as the umbilical vein and the blood vessels lining the aorta 
(20).  These results would suggest that the Eph family of receptors play a critical 
function in vascular development. 
 In adult tissue, Eph receptors also play a pivotal role in angiogenesis.  EphA2, in 
particular, has been linked to pathological angiogenesis, including tumor 
neovascularization.  The first functional evidence that EphA2 participates in 
angiogenesis came from work in corneal angiogenesis.  Soluble EphA2-Fc was able 
to suppress ephrinA1 or VEGF induced endothelial cell survival, migration, and 
corneal angiogenesis (21).  Similarly, inhibition of EphA2 expression with EphA2 
antisense oligonucleotides also suppressed ephrinA1 and VEGF induced migration of 
endothelial cells (21).  EphA2 signaling has also been demonstrated to be important 
in tumor angiogenesis.  Tumor xenografts of MDA-MB-435 human breast cancer 
cells or KS1767 Kaposi’s sarcoma cells in nude mice demonstrated that both EphA2 
and ephrinA1 were expressed in endothelial cells and tumor cells (22).  Soluble 
EphA2-Fc receptor treatment suppressed tumor growth and tumor angiogenesis in 
murine 4T1 mammary carcinomas (23).  Endothelial cells deficient in EphA2 
expression showed impaired migration in response to 4T1 breast cancer cells (24).  
EphA2 deficiency also displayed defects in endothelial cell assembly and migration 
in response to ephrinA1 (25).  EphrinB2 and EphB4 have also been reported to be 
involved in angiogenesis.  Stimulation of endothelial cells with either soluble dimeric 
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forms of ephrinB ligand or EphB receptor promoted angiogenesis (15, 26).  These 
results would suggest that both forward signaling, through the receptor, and reverse 
signaling, though the ligand, play essential roles in angiogenesis.  EphrinB2 
expression has also been detected in tumor vasculature in many types of cancer.  
Expression of the extracellular domain (ECD) of EphB4 on tumor cells has been 
reported to increase tumor growth due to its effects on tumor vascularization (27, 28).  
These data suggest that Eph receptors and the ephrin ligands play a pivotal role in 
cancer, at least in part by tumor angiogenesis.  I identified several tyrosines that are 
phosphorylated on EphA2 in vascular endothelial cells.  The phosphorylated tyrosine 
residues are important in mediating EphA2 interaction with signaling molecules 
involved in endothelial cell function.  These data are presented in Chapter V. 
 
EphA2 in Cancer 
 EphA2 has been investigated in many types of cancers including prostate, colon, 
lung, colorectal, cervical, ovarian, and breast cancer.  Generally, these studies found 
that EphA2 expression correlated with tumor progression.  EphA2 was reported to be 
upregulated by as much as 60-92% in clinical breast cancer specimens [Brantley-
Sieders and Chen, unpublished data; (29, 30)].  Interestingly, an independent group 
reported that EphA2 expression was increased in both breast tumors as well as tumor 
endothelium (22, 23).  In addition, high EphA2 expression was detected in 93% of 
prostate cancer specimens (31), 88.8% of cervical cancers (32), 74.1% of non-small 
cell lung carcinomas (33), and 92.8% of renal cell carcinomas (34).  These studies 
indicate that EphA2 is overexpressed in many types of human cancers. 
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 Several studies have shown that EphA2 is upregulated in both tumor cells and 
tumor associated endothelium.   In a study by Kataoka et al, they found that EphA2 
was expressed in colorectal tumors and tumor microvessels (35).  Ogawa et al 
reported that EphA2 was upregulated in tumor cells and tumor vasculature in breast 
cancer (22).  These data are consistent with previous reports that indicate EphA2 
plays an important role in angiogenesis.  Overall, the data would suggest that EphA2 
may have a role in both tumor cells and tumor microenvironment. 
 EphA2 is believed to play an important role in tumor progression, as EphA2 
expression has been correlated with tumor malignancy.  Elevated EphA2 expression 
was correlated with disease stage in colorectal, lung, ovarian, and renal cancers (33-
36).  High EphA2 expression correlated with poor patient survival in cervical cancer, 
ovarian cancer, and melanomas (32, 37).  Several studies have also shown that 
elevated EphA2 expression correlated with tumor metastasis.  In non-transformed 
MCF-10A mammary epithelial cells, overexpression of EphA2 was sufficient to 
transform those cells (30).  Overexpression of EphA2 in these cells induced colony 
formation in soft agar, increased invasion in Matrigel, and, when implanted in mice, 
formed tumors (30).  In pancreatic cancer cells, overexpression of EphA2 was found 
to increase resistance to anoikis (38).  Conversely, downregulation of EphA2 levels 
by siRNA, knockdown by antisense oligonucleotides, or antibody mediated 
degradation resulted in a decrease in tumorigenicity in cancer cell lines.  Knockdown 
of EphA2 levels in several pancreatic cancer cells by siRNA, resulted in decreased 
Matrigel invasion, increased anoikis, and increased apoptosis (38).  Treatment with 
EphA2-Fc, which binds and sequesters the ephrinA ligand, prevents endogenous 
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EphA2 activation and impairs tumor progression in vivo.  Inhibition of EphA2 
activation by EphA2-Fc treatment has been reported to inhibit tumor growth in mouse 
models of breast cancer and pancreatic cancer (23, 39).  Interestingly, it has been 
reported that although EphA2 is overexpressed in many types of cancers, the EphA2 
receptor is underphosphorylated in these cases (40).  However, the 
underphosphorylated EphA2 receptor still retains kinase activity (40).  These data 
would suggest that EphA2 plays an important role in tumor progression.  Although, it 
remains unclear whether EphA2 kinase activity is essential for this role.  The work in 
my dissertation shows EphA2 kinase functions to promote tumor progression.  These 
data are presented in Chapter III. 
 
EphA2 Signaling 
 EphA2 plays an important role in cellular function as indicated by its ubiquitous 
expression.  Unlike other receptor tyrosine kinases, EphA2 is primarily thought to 
regulate cell adhesion, cell migration, and cell survival, although EphA2 forward 
signaling has been shown to inhibit tumor cell proliferation in a number of cancer cell 
lines (41, 42).  EphA2 activation can promote multiple signaling pathways (Fig 3).  
Two major common downstream signaling pathways that are influenced by EphA2 
signaling are the Rho family of GTPases and Ras-Raf-MAPK pathways. 
 
EphA2 and the Rho family of GTPases 
 Eph signaling has been shown to affect cell morphology and cell migration.  The 
Rho family of GTPases are a class of molecules that have emerged as downstream  
 10
 
 
 
 
Figure 3.  EphA receptor signaling.  Many proteins have been currently identified to 
interact with the Eph receptors.  Many of the proteins converge on similar signaling 
cascades.  Some of the common downstream signaling pathways of Eph receptor 
activation are activation or inhibition of the Rho family of GTPases, activation or 
inhibition of the Ras-MAPK pathway, and downstream effectors of FAK signaling. 
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signaling proteins of Eph receptor signaling.  Rho proteins cycle between an inactive 
(GDP bound) and active (GTP bound) conformation.  Cycling between GTP-bound 
Rho and GDP-bound Rho is catalyzed by two classes of proteins, guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs).  Rho GTPases 
regulate cell shape and cell movement by regulating actin cytoskeleton dynamics (43-
45).  The three most well characterized members are: RhoA, Rac1, and Cdc42.  RhoA 
promotes the formation of stress fibers and focal adhesions.  Rac1 controls the 
formation of lamellipodis and Cdc42 regulates filopodia formation (46).  Activation 
of the Eph receptors has been shown to activate or repress Rho GTPases depending 
on the cell type. 
 In neuronal cells, Rho activation stimulates growth cone collapse and inhibits 
axon regeneration (47-49).  It has been reported that Eph receptor activation promotes 
cell repulsion in the developing nervous system, which mediates growth cone 
collapse (50).  For example, activation of EphA2 receptors in retinal ganglion cells 
promotes growth cone collapse.  This process is mediated by ephrinA5 treatment.  
Stimulation of these cells with ephrinA5 ligand, increases levels of GTP bound RhoA 
and induces activation of Rho-associated kinase (ROCK), a downstream effector of 
RhoA (50).  Although levels of activated RhoA are increased, the levels of activated 
Rac1 are decreased(50).  The Eph mediated activation of Rho family GTPases is not 
restricted to neuronal cells.  In vascular smooth muscle cells, stimulation with 
ephrinA1 resulted in RhoA activation and stress fiber formation suggesting that 
ephrinA1 might regulate vascular contractility (51).  Consistent with the results from 
neuronal cells, activation of RhoA and inactivation of Rac was observed in the 
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vascular smooth muscle cells (52).  In endothelial cells, activation of EphA2 leads to 
the activation of Rac1 and not RhoA, and was found to be important in endothelial 
cell assembly and migration (25).  These data would suggest that Eph receptor 
signaling may have differential effects based on cell type.  However, it appears that 
Rho family GTPase signaling is a pivotal pathway downstream of Eph activation. 
 There are several ways by which the Eph receptors can influence Rho activation.  
RhoGEFs are proteins that catalyze the exchange of GDP for GTP on the Rho 
protein.  There have been several RhoGEFs that have been characterized to interact 
with EphA receptors (Table 1).  One of the first RhoGEFs identified as interacting 
with EphA4 was Ephexin.  Ephexin is primarily expressed in the nervous system, but 
is also expressed at lower levels in the kidney, liver and testes (53, 54).  Ephexin has 
been reported to activate RhoA and to a lesser extent Cdc42, but not Rac1.  Although, 
overexpression of Ephexin in neuronal cells enhanced RhoA activation, Cdc42 
activation, and only moderately activated Rac1 (54, 55). Another member of the 
Ephexin family of exchange factors also interacts with EphA4.  Vsm-RhoGEF is 
closely related to Ephexin.  Ephexin and Vsm-RhoGEF both contain tandem Dbl 
homology and pleckstrin homology domains.  However, Vsm-RhoGEF is only 
expressed in vascular smooth muscle cells.  Vsm-RhoGEF activates RhoA, but 
inactivates Rac1 (51, 52).  Another family of RhoGEFs that associates with EphA2 is 
the Vav family exchange factors.  The association of Vav3 with EphA2 participates in 
endothelial cell function, as Vav2/3 deficient endothelial cells fail to migrate or 
assemble in response to ephrinA1 treatment (56).  The defect in migration and 
assembly is at least in part due to defective Rac1 activation (56). 
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 Interestingly, Ephexin has been shown to interact with EphA4 in the kinase 
domain (54).  However, the association of Vav3 with EphA2 occurs within the 
juxtamembrane domain of EphA2 (56).  It is currently unclear how the association of 
these RhoGEFs with the Eph receptors affects Rho activation.  One possibility is that 
it localizes the exchange factors at the cell membrane to produce localized activation 
of the Rho proteins.  Another possibility is that the Eph receptors can phosphorylate 
these RhoGEFs to affect its catalytic activity.  EphA4 has been reported to directly 
phosphorylate Vsm-RhoGEF (51).  In the case of Vav2, ephrinA1 stimulation of 
neuronal cells induced tyrosine phosphorylation of Vav2 (57).  The signaling 
pathways that mediate these effects are not completely known.  It has been reported 
that SHIP2, a phosphatase, can influence Rho activation by production of lipid 
products to relieve the inhibition of the RhoGEF’s catalytic activity.  Zhuang et al 
demonstrated SHIP2 can associate with EphA2.  SHIP2 interaction with EphA2 
increased in PI-3kinase activity, which ultimately lead to an increase in Rac1 
activation (58).  CrkII has been shown to interact with activated EphA3 receptor in 
293T cells overexpressing EphA3 (59).  Stimulation of EphA3 with ephrinA5 caused 
RhoA activation, retraction of cellular protrusions, and decreased cell adhesion (59).  
It remains unclear how Eph receptor signaling can activate or inactivate the Rho 
family of GTPases.  I identified several phosphorylated tyrosine residues that are 
important in mediating interactions with several of these proteins and the functional 
relevance of these interactions.  The data are presented in Chapter V. 
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EphA2 and MAPK pathway 
 Another prominent pathway that has been shown to be downstream of EphA2 
signaling is the MAPK pathway.  Interestingly, until recently it was generally 
believed that Eph receptors do not regulate cell proliferation.  However, several 
different publications have demonstrated that Eph receptor signaling can influence the 
MAPK signaling cascade.  As there have been published reports of EphA2 signaling 
activating, as well as inhibiting MAPK activation, it remains to be determined exactly 
how EphA2 is linked to the MAPK pathway. 
 One of the first studies showing the relationship between EphA signaling and 
MAPK activation was performed using several different cell types.  This study 
demonstrated ephrinA1 treatment of these cells inhibited Erk activation.  In prostate 
epithelial cells (PRNS-1-1 and PC-3), mouse embryonic fibroblasts, and bovine 
endothelial cells, ephrinA1 treatment of these cells rapidly reduced Erk 
phosphorylation (41).  This affect was likely mediated by inhibition of Ras-Raf 
signaling.  Activation of EphA resulted in a decrease in activated Ras and could be 
compensated for by overexpression of Ras (41).  In several recent publications, 
EphA2 has been reported to activate MAPK signaling.  Pratt et al reported that MDA-
MB-231 human breast cancer cells treated with ephrinA1-Fc induced Erk 
phosphorylation (60).  These results were confirmed in several other breast cancer 
cell lines and also in PC-3 prostate cancer cells.  The activation of the MAPK kinase 
cascade in this situation was mediated by SHC and Grb2 association with the EphA2 
receptor, as expression of a dominant negative SHC could inhibit MAPK activation 
(60).  Interestingly in a recent report, Macrae et al reported that the Ras-Raf-MAPK 
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pathway could upregulate transcription of EphA2 (42).  Analysis of mRNA derived 
from NIH3T3 cells that expressed a constitutively activated Raf revealed that EphA2 
was a target of Ras-MAPK activation, and these results were also confirmed by 
protein analysis.  EphA2 signaling can attenuate EGF mediated Erk activation in 
several different breast cancer cell lines.  Interestingly, analysis of a wide array of 
breast cancer cell lines revealed an inverse relationship between EphA2 and ephrinA1 
expression (42).  In general, malignant breast cancer cells that lack E-cadherin 
expression exhibited high expression of EphA2, while the highest level of ephrinA1 
expression were found on cells that retained epithelial cell characteristics.  Recent 
studies from our laboratory revealed that EphA2 cooperates with Neu/ErbB2 receptor 
tyrosine kinase to enhance the activity of both RhoA and Ras/MAPK in tumors and 
cells derived from MMTV-Neu transgenic mice, as well as in MCF-10A cells 
overexpressing the human homolog of ErbB2, Her2 (61). 
 EphA2 signaling has been clearly demonstrated to affect MAPK activation.  
However, it uncertain how EphA2 may affect activation, as in the case of breast 
cancer cells, or inhibition, in prostate cancer cells, of MAPK.  One possible 
rationalization between these two opposing observations is that EphA2 signaling 
could mediate both activation and inhibition of MAPK.  The signaling pathways 
involved may be quite different, as SHC association with EphA2 resulted in 
activation of MAPK, while association of p120 RasGAP could mediate inhibition of 
MAPK activation as observed in EphB2 (62).  One of the aims of this study is to 
identify the different phosphorylated tyrosine sites on EphA2 that could interact with 
different signaling molecules, so as to provide the molecular and biochemical tools to 
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address these questions within the field.  I identified several phosphorylated tyrosine 
residues that are important in mediating interactions with different signaling proteins 
and the functional relevance of these interactions.  The data are presented in Chapter 
V. 
 
EphA2 signaling and cell-cell adhesion 
 One of the hallmarks of cancer progression and invasiveness is downregulation of 
E-cadherin.  As mentioned earlier, Macrae et al reported that EphA2 expression 
inversely correlated with E-cadherin expression in breast cancer cells (42).  There 
have been several studies that have linked EphA2 signaling to cell-cell adhesion 
molecules. 
 One of the first studies that demonstrated a relationship between EphA2 and E-
cadherin showed that EphA2 and E-cadherin colocalized at sites of cell-cell contacts.  
Disruption of cell-cell contacts by treatment with a calcium chelator dramatically 
reduced EphA2 phosphorylation (40).  This study demonstrated that although EphA2 
is upregulated in many cancer cells, it is underphosphorylated in comparison to 
normal mammary epithelium.  This study suggests that loss of E-cadherin could 
mediate this effect in cancer cells.  Orsulic et al reported that loss of E-cadherin could 
downregulate EphA2 mRNA and protein levels, and this could be rescued by re-
expression of E-cadherin (63).  Overexpression of E-cadherin in NIH3T3 cells 
regulated the localization of EphA2 to the surface membrane and overexpression of a 
dominant negative E-cadherin construct in HT-29, colon cancer cells, would 
relocalize EphA2 into a perinuclear region (63).  These studies identify the functional 
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dependence of EphA2 on E-cadherin expression.  It is unclear whether EphA2 can 
affect the adherens junction proteins, i.e. E-cadherin, β-catenin, α-catenin, and p120 
catenin.  Since E-cadherin and EphA2 colocalize to the plasma membrane, it is 
possible that these proteins can directly interact.  However, Zantek et al and Orsulic et 
al were unable to show co-immunoprecipitation of these proteins with EphA2.  In a 
recent publication, Potla et al reported that stimulation of HT-29 cells with ephrinA1-
Fc could induce EphA2, E-cadherin, and β-catenin tyrosine phosphorylation (64).  
The significance in the increase phosphorylation of the adherens junction proteins are 
not known, tyrosine phosphorylation of these proteins could potentially disrupt cell-
cell adhesion.  Tanaka et al recently reported that EphA2 could directly associate with 
and phosphorylate Claudin-4 (65).  The interaction and phosphorylation of Claudin-4 
and EphA2 resulted in decreased interaction of ZO-1 with Claudin-4.  The decreased 
association of Claudin-4 and ZO-1 resulted in a reduction in tight junction function 
and an increase in intracellular permeability of these cells (65).  However, these 
results have not been observed for EphA2 and adherens junction proteins.  In this 
dissertation, I show for the first time that EphA2 signaling through RhoA leads to 
weakening of cell-cell adhesion.  The data are presented in Chapter IV. 
 
Summary 
 Since its discovery, there has been a wealth of research on Eph signaling.  Eph 
signaling affects many different signaling pathways.  Ephrin ligand binding induces 
Eph receptor phosphorylation.  Many phosphorylated tyrosines have been mapped to 
the juxtamembrane and kinase domain of the Eph receptor.  These phosphorylated 
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tyrosines on the Eph receptor serve as docking sites for a number SH2/PTP domain 
containing proteins, such as Ras-GTPase-activating protein (RasGAP), Src family of 
tyrosine kinases, low molecular weight phosphotyrosine phosphatase (LMW-PTP), 
phospholipase Cγ, phosphatidylinositol 3-kinase, SLAP, Grb2, Grb10, and Nck 
(Table 1).  One of the other goals of this dissertation was to dissect the signaling 
mechanisms underlying EphA2 phosphorylation for transduction of its cellular signal.  
To thoroughly address EphA2 signaling, it will be essential to identify important 
EphA2 phosphorylated tyrosine residues and to map the interactions of these 
signaling molecules to EphA2.  I identified several phosphorylated tyrosine residues 
that are important in mediating interactions with several of these proteins and the 
functional relevance of these interactions are presented in Chapter V. 
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Table 1.  EphA receptor interacting proteins. 
Eph 
Receptor 
Interacting 
protein 
Eph binding region Interacting 
domain 
Reference 
EphA2 c-Cbl NT NT (66) 
 FAK NT NT (67) 
 LMW-PTP NT NT (68) 
 P85β-PI3K kinase SH2 (69) 
 SHP2 NT NT (67) 
 SHIP2 NT NT (58) 
 SLAP NT NT (70) 
 p120RasGAP NT NT (71) 
 Src NT NT (72) 
 SHC NT NT (60) 
 Vav3 juxtamembrane SH2 (56) 
EphA3 Abl NT SH2 (73) 
 Fyn, Src, Yes NT SH2 (74) 
 CrkII juxtamembrane SH2 (52) 
EphA4 Abl NT NT (73) 
 Ephexin kinase DH-PH (54) 
 Vsm-RhoGEF NT DH-PH (51) 
 p59Fyn juxtamembrane SH2 (75) 
 SHEP1 NT SH2 (76) 
 Src NT SH2 (74) 
EphA7 AF6 PDZ PDZ (77) 
 GRIP,PICK PDZ PDZ (78) 
EphA8 Fyn juxtamembrane SH2 (79) 
 P110γ-PI3K juxtamembrane NT (80) 
 
Modified from (81). 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Antibodies and reagents.  Antibodies used for immunoblot include anti-EphA2 
(1:1000, Upstate Biotechnology), anti-phosphotyrosine (1:250, Santa Cruz 
Biotechnology), anti-myc (1 : 500; Cell Signaling Technology), anti-ephrin-A1 (1 : 
500), anti-cleaved caspase-3 (1 : 100, Cell signaling), anti-PCNA (0.5 μg/ml, 
Neomarkers), anti-p190 RhoGAP (1:1000, Transduction Laboratory), anti-E-cadherin 
(0.1 μg/ml, Transduction Laboratory), anti-p120 (0.1 μg/ml, Transduction 
Laboratory), anti-β catenin (1:5000, Sigma), anti-α catenin (1:5000, Sigma), anti-
tubulin (1:1000, Sigma), anti-phospho-Src (Y416) (1:1000, Cell Signaling 
Technology), anti-src (1:1000, Cell Signaling Technology), anti-Rac1 and anti-Cdc42 
(1:1000; Transduction Laboratories), and anti-RhoA (1:200, Santa Cruz 
Biotechnology).  Anti-LMW-PTP (1:2000) was a kind gift from Dr. Takamune 
Takahashi.   Recombinant ephrinA1-Fc proteins were purchased from R&D Systems 
(Minneapolis, MN).  ROCK inhibitor, Y27632, and Src inhibitor, PP2, were 
purchased from Calbiochem.   
 
Immunoprecipitation of EphA2 from cell lysates was performed with anti-EphA2 
antibody (2 µg; Upstate Biotechnology), and p85 was immunoprecipitated by anti-
FLAG (M2)-agarose beads (Sigma). Recombinant ephrin-A1-Fc proteins were 
purchased from R&D Systems (Minneapolis, MN). Growth factor-reduced Matrigel 
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was purchased from BD Biosciences. Transient transfection was performed using 
Lipofectamine 2000 (Invitrogen). 
 
Plasmids and viruses.  EphA2/LZRS and EphA2-ΔC/LZRS were generated from 
existing plasmids.  EphA2 was digested from EphA2/pcDNA3.0 with EcoRI.  The 
EphA2 fragment was ligated into the LZRS EcoRI site.  EphA2-ΔC/LZRS was 
generated by digesting EphA2-ΔC/pcDNA3.1/hisB with PmeI and EcoRI.  The LZRS 
vector was digested with AfeI and EcoRI and EphA2-ΔC was ligated into LZRS.  
P190 RhoGAP/LZRS and p190 30-1/LZRS were described previously.  LMW-PTP 
C12S/pBabe and LMW-PTP/pGEX were subcloned from plasmids that were 
described previously.  Adenovirus expressing consitutively active RhoA (Q63L) was 
purchased from Cell Biolabs (San Diego, CA).  Adenoviruses expressing control β-
galactosidase was described previously. 
 
EphA2 Mutagenesis.  EphA2 mutations were generated by PCR amplification using 
EphA2 specific primers containing tyrosine to phenylalanine mutations (mutations 
shown in lower case).  The fragments were digested with AgeI and BsiWI (for 
tyrosine mutations 593-846) and BamHI and BlpI (for tyrosine mutations 921-959) 
and ligated into the digested plasmids pcDNA3.0-EphA2 and LZRS-EphA2. All 
mutations were verified by DNA sequencing. The dominant-negative EphA2 receptor 
mutant, W42-EphA2, carries a D738N point mutation that is analogous to that 
identified in the spontaneously occurring dominant-negative W42 mutant allele of c-
kit (Reith et al., 1990). Mutation of this conserved residue has previously been shown 
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to confer dominant-negative signaling properties in c-Kit and other RTKs in cell-
based assays. The myc-tagged-dominant negative EphA2 cytoplasmic domain 
truncation mutant (EphA2-DeltaC) was generated by PCR amplification of the 
extracellular and transmembrane domain of EphA2 and subcloned into pcDNA 3.1 
(Invitrogen). 
 
Cell culture and retroviral infection.  MCF-10A is a spontaneously immortalized, 
but non-transformed human mammary epithelial cell line that was derived from the 
breast tissue of a patient with fibrocystic changes.  MCF-10A cells exhibit numerous 
features of normal breast epithelium, including the lack of tumorigenicity in nude 
mice, the lack of anchorage-independent growth, and the dependence on growth 
factors and hormones for proliferation and survival.  MCF-10A cells were obtained 
from American Type Culture Collection and cultured in 5% horse serum (Hyclone), 
20 ng/ml EGF (Sigma), 0.5 μg/ml hydrocortisone (Sigma), 100 ng/ml Cholera Toxin 
(Calbiochem), 10 μg/ml insulin (Sigma), and 1% penicillin-streptomycin (Life 
Technologies, Inc) in 50:50 DMEM/F12.  MCF-10A cells were infected with LZRS 
retroviruses co-expressing EphA2 (wildtype or ΔC)-IRES-GFP and FACS sorted for 
comparable EphA2 receptor levels.  
 
Endothelial Cell Culture and Retroviral Infection—Wild-type or EphA2-deficient 
primary murine pulmonary microvascular endothelial cells were isolated from 1-3-
month-old mice derived from H-2Kb-tsA58 transgenic "Immorto-mouse" 
background. These cells were grown at 33 °C in EGM-2 medium supplemented with 
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interferon-γ (10 ng/ml), a permissive condition that allows the expression of SV40 T-
antigen (TAg). The EphA2-deficient endothelial cells were infected with LZRS 
retroviruses co-expressing IRES-EphA2 (wild-type or mutant)-green fluorescent 
protein and sorted by a fluorescence-activated cell sorter for comparable EphA2 
receptor levels. Cells were placed at physiologic temperature (37 °C) for 4 days to 
down-regulate thermolabile TAg before experiments. 
 
Hanging drop aggregation assay.  MCF-10A cells were trypsinized and resuspended 
at a concentration of 500,000 cells/ml of growth media.  Approximately 15,000 cells 
(30 μl of cell suspension) were pipetted on the lid of a 24 well plate and the 
corresponding wells were filled with 1 ml of growth media.  The culture dish lid was 
then carefully inverted over the wells, causing the cells to be suspended from the lid 
as hanging drops.  Cells were incubated overnight at 37°C.  Cell-cell adhesion was 
assessed by microscopy both before and after vigorous pipetting (20 times with a 200 
μl Gilson pipette tip). 
 
Calcium switch assay.  MCF-10A cells were grown to approximately 80% 
confluence.  The cells were then serum starved overnight with OptiMem (Invitrogen).  
The following day, the media was aspirated and the cells were washed once with PBS 
and DMEM containing no calcium or magnesium (Invitrogen) was added.  The cells 
were cultured in calcium free media for 8 hrs and 24 hrs (to ensure complete lost of 
surface E-cadherin).  For the 24 hr time point, the calcium free DMEM media was 
aspirated and the cells were washed once with PBS.  Calcium free DMEM containing 
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1.8 mM CaCl2 (Sigma) was added to the cells for 1 hr and 3 hr.  For the experiments 
using the ROCK inhibitor (Y27632), cells were treated with 10 μM Y27632 for the 
duration of the calcium depletion and/or when the calcium was added back.  The cells 
were then fixed with ice-cold methanol for visualization by immunofluorescence 
staining. 
 
Rhotekin pull-down Assay.  For RhoA activation assays, MCF-10A or MCF-10A 
cells expressing mutated EphA2 were serum starved overnight with serum free 
Optimem medium followed by stimulation with ephrinA1 (1 μg/ml).  Lysates were 
prepared and incubated with Rhotekin-GST beads as previously described (25).  
Activated RhoA (or total RhoA in lysates) were detected by immunoblot using anti-
RhoA antibodies (Santa Cruz).  Relative levels of GTP-bound RhoA were quantified 
by densitometry using Scion Image 1.62c software analysis. 
 
Immunoprecipitation and immunofluorescence. MCF-10A cells were lysed 
with RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholic 
Acid, 0.1% SDS, pH=7.4) or Brij Lysis Buffer (10 mM Tris, pH=7.5, 150 mM NaCl, 
2 mM EDTA, 0.88% Brij 97, 1.25% NP-40) for MBP-EphA2, GST-LMW-PTP 
pulldown experiments, and co-immunoprecipitation of EphA2 and Src.  For E-
cadherin co-immunoprecipitations, cells were lysed in CSK lysis buffer (10 mM 
PIPES, pH=6.8, 10 mM NaCl, 300 mM sucrose, 3 mM MgCl2, and 0.5% NP-40 
(solution pH=7.4)).  All lysis buffers contained the following concentrations of 
protease inhibitors: 1 mM PMSF, 5 μg/ml leupeptin, 2 μg/ml aprotinin, 1mM Sodium 
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Orthovanadate, and 1 mM EDTA.  EphA2, E-cadherin, and p190 RhoGAP were 
immunoprecipitated using anti-EphA2 (2 μg, Upstate Biotechnology), anti-E-
cadherin (4 μg, Transduction Laboratory), and anti-p190 (2 μg, Transduction 
Laboratory) antibodies.  In brief, MCF10A cell lysates were incubated with antibody 
(Protein A/G Sepharose) or fusion protein (GST or MBP beads) for 2 hrs at 4 degrees.  
The samples were washed three times with PBS.  Samples were resolved by SDS-
PAGE and western blotted for respective proteins.  For immunofluorescence, cells 
were washed with PBS and fixed in methanol for 7 minutes at -20 degrees.  Cells 
were stained with anti-E cadherin and anti-p120 antibodies (0.1 μg/ml and 0.5 μg/ml, 
respectively, Transduction Laboratory).  Images were taken on LSM 310 META 
confocal microscope. 
 
LMW-PTP Phosphatase Assay.  Cell lysates were obtained as described above.  The 
samples were immunoprecipitated for LMW-PTP using an anti-LMW-PTP antibody 
that was generously provided by Dr. Takamune Takahashi.  The samples were 
washed twice with PBS and once with phosphatase buffer (50 mM HEPES, pH=4.5, 
1 mM DTT, 0.1% BSA).  The samples were resuspended in phosphatase reaction 
buffer.  200 μM 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP, Invitrogen) 
was dissolved in phosphatase buffer and was added to each sample. An aliquot of the 
supernatant was transferred to a 96 well plate and the samples were read with an 
excitation of 350 nm and emission of 450 nm following a time course.  
 
 26
LC-MS Analysis.  LC-MS was performed by the Proteomics Laboratory in the 
Vanderbilt Mass Spectrometry Research Center. Resolved mouse EphA2 was excised 
from SDS-polyacrylamide gels for in-gel digestion with trypsin (82). The resulting 
peptides were separated by reverse phase high pressure liquid chromatography that is 
coupled directly with automatic tandem MS (LC-MS) using a ThermoFinnigan LTQ 
ion trap mass spectrometer equipped with a Thermo surveyor autosampler and 
Thermo Surveyor HPLC pump, nanospray source, and Xcalibur 1.4 instrument 
control. HPLC separation of the tryptic peptides was achieved with a 100 mm x 11-
cm C-18 capillary column (Monitor C18, 5 µm, 100 Å; Column Engineering), at a 0.7 
µl min-1 flow rate. Solvent A was H2O with 0.1% formic acid, and solvent B was 
acetonitrile containing 0.1% formic acid. The gradient program was as follows: 0-3 
min, linear gradient from 0-5% B; 3-5 min, 5% B; 5-50 min, linear gradient to 50% 
B; 50-52 min, linear gradient to 80% B; 52-55 min, linear gradient to 90% B; 55-56 
min, 90% B in solvent A. MS/MS scans were acquired using an isolation width of 2 
m/z, an activation time of 30 ms, and activation Q of 0.250 and 30% normalized 
collision energy using one microscan and an ion time of 100 for each scan. The mass 
spectrometer was tuned prior to analysis using the synthetic peptide TpepK 
(AVAGKAGAR). Typical tune parameters were as follows: spray voltage of 1.8 kV, 
a capillary temperature of 160 °C, a capillary voltage of 60 V, and tube lens 120 V. 
Initial analysis was performed using data-dependent scanning in which one full MS 
spectrum, using a full mass range of 400-2000 atomic mass units, was followed by 
three MS/MS spectra. Incorporated into the method was a data-dependent scan for the 
neutral loss of phosphoric acid or phosphate (-98, -80), such that if these masses were 
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found, an MS/MS/MS of the neutral loss ion was performed. Peptides were identified 
using a cluster-compatible version of the SEQUEST algorithm (83, 84), using a 
mouse subset of proteins from the nonredundant data base from NCBI downloaded in 
January, 2004 containing 90, 197 sequences. Sequest searches were done on a high 
speed, multiprocessor Linux cluster in the Advanced Computing Center for Research. 
In addition to using the SEQUEST algorithm to search for phosphorylation on 
serines, threonines, or tyrosines, the data were also analyzed using the Pmod 
algorithm (85). All possible modified peptides were verified by manual inspection of 
the spectra. 
 
Phosphopeptide Mapping by Two-dimensional Chromatography.  EphA2-null 
murine pulmonary microvascular endothelial cells reconstituted with either wild-type 
or mutant EphA2 were stimulated with ephrin-A1 for 15 min. Cells were lysed and 
EphA2 was immunoprecipitated and phosphorylated in the presence of [γ-32P]ATP, 
as described under "Immunoprecipitation, Western Blot Analysis, and Kinase Assay." 
Immunoprecipitates were separated by SDS-PAGE and transferred to polyvinylidene 
difluoride membrane. Polyvinylidene difluoride membrane containing 32P-labeled 
EphA2 receptor was excised, and proteins were digested in membrane with 1 mg/ml 
L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin. The resulting 
peptide mixture was resolved in two dimensions on 20 cm x 20-cm thin layer 
cellulose plates by electrophoresis followed by ascending chromatography. 
Electrophoresis was performed at pH 1.9 in 10:1:189 acetic acid/pyridine/water for 3 
h at 250 V with ~10 p.s.i. of pressure. Ascending chromatography was carried out in 
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625:19:48:29: 279 isobutyric acid/n-butanol/pyridine/acetic acid/water for 11 h or 
until the buffer was about 1 cm from the top of the TLC plate. The plates were dried 
and subjected to autoradiography overnight at -70 °C with an intensifying screen. 
 
Kinase assay.  Wild-type and EphA2-deficient lung microvascular endothelial cells 
were isolated from EphA2 knockout mice and were infected with LZRS retrovirus 
expressing wild-type or W42 mutant form of EphA2 receptor. Parental and infected 
cells were serum starved for 24 h in serum-free Optimum medium followed by 
stimulation with ephrin-A1 (1 mug/ml). Cells were lysed and EphA2 were 
immunoprecipitated with an anti-EphA2 antibody (2 mug, C-20, Santa Cruz) in 
Triton X-100 buffer (20 mM Tris-Cl, 150 mM NaCl, 25 mM beta-glycerophosphate, 
2 mM EDTA, 10% glycerol,1% Triton X-1000, 1 mM DTT, 1 mM sodium 
orthovanadate, 10 mug/ml Leupeptin, and 1 mM PMSF). The samples were 
resuspended in 25 mul kinase buffer [20 mM HEPES pH=7.6, 20 mM beta-
glycerophosphate, 0.1 mM sodium orthovanadate, 10 mM MgCl2, 50 mM NaCl, 1 
mM DTT, 200 mM ATP, and 20 muCi [γ-32P] ATP (NEN, NEG502A500UC)], 
incubated at 30°C for 25 mins, resolved on a 8% SDS-polyacrylamide gel, and 
transferred to nylon membrane for autoradiography. The blot was stripped and re-
probed with anti-EphA2 to ensure equal loading. 
 
Orthotopic tumor transplantation.  BALB/c mice, 10 weeks of age, were injected 
with 1 times 105 4T1 cells in the left inguinal mammary gland. The primary tumors 
were harvested 1 week after injection. Tumor size was assessed by caliper 
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measurements, and the tumor volume was calculated by the following formula: 
Tumor volume=0.52 times width2 times length. BALB/c female animals (10 weeks 
old) were obtained from Harlan Sprague–Dawley and housed under pathogen-free 
conditions. All experiments were performed in accordance with AAALAC guidelines 
and with Vanderbilt University Institutional Animal Care and Use Committee 
approval. 
 
Histologic analyses.  Tumors isolated from BALB/c female mice were processed for 
histology by overnight fixation in 10% neutral-buffered formalin (Fisher Scientific) at 
4°C followed by paraffin embedding and preparation of 7 mum sections. Apoptosis 
was assessed by TUNEL assay using an Apotag red in situ apoptosis detection kit 
(Serologicals Corporation, Norcross, GA, USA) as described previously. Images were 
captured using an Olympus BX60 microscope and digital camera. The percentage of 
apoptotic nuclei was calculated based on the number of TUNEL+nuclei divided by 
the number of DAPI+nuclei (total nuclei) in four random 20 times fields/section. 
Proliferation was assessed by quantification of PCNA-positive nuclei as described 
previously (Brantley et al., 2002; data not shown). 
 
Metastasis assay.  For the experimental metastasis studies, BALB/c mice were 
administered with 1 times 104 4T1 cells intravenously. The lungs were harvested 12 
days after injection. The lungs were fixed by intratracheal infusion of 10% neutral 
formalin and embedded as described above for primary tumors. Surface lung 
metastases were scored in a blind fashion under the dissecting microscope. For 
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spontaneous metastasis studies, 10-week-old BALB/c females were injected with 5 
times 105 4T1 cells in the left inguinal mammary gland as described (Yang et al., 
2004). The primary tumors and lungs were harvested after 21 days. Lungs were fixed 
for 24 h in 10% neutral-buffered formalin at 4°C, dehydrated, and cleared by washing 
three times, 1 h each, in xylenes (Fisher Scientific). Lungs were rehydrated and 
stained in Mayer's hematoxylin (Sigma-Aldrich) for 1 h at room temperature. After 
briefly washing in tap water, lungs were destained in 15-min washes with 1% v/v 
HCl, dehydrated and cleared in xylenes. The lungs were then equilibrated into methyl 
salicylate (Sigma) for enumeration of metastases. 
 
Wound closure assay.  The wound closure assay was described previously (Cheng et 
al., 2002). Briefly, the 4T1 cells were grown to confluence in six-well tissue culture 
plates. Replicate circular 'wounds' were generated in confluent 4T1 cell monolayers. 
Residual fractional 'wound' areas were measured at 2, 4, 6, 8, and 24 h. Pictures were 
taken with an Olympus BX60 microscope and digital camera. The area of the wound 
was calculated using Scion Image software 1.62c (National Institute of Health, 
Bethesda, MD) for each time point. 
 
Statistical analyses.  Statistical analyses were performed using Microsoft Excel 
software using analysis of variance (ANOVA) for comparison of data among 4T1 
cells or 4T1 cells expressing wild-type or mutant forms of EphA2 receptor; or 
unpaired Student's t-tests for comparison of data from control 4T1 cells with 4T1 
cells expressing DeltaC or W42 EphA2 mutants. All tests of significance were two 
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sided, and differences were considered statistically significant when P-value<0.05. 
All data were expressed as means plus minus s.e.m. 
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CHAPTER III 
 
A KINASE-DEPENDENT ROLE FOR EPHA2 RECEPTOR IN PROMOTING 
TUMOR GROWTH AND METASTASIS 
 
Introduction 
 
 Receptor tyrosine kinases (RTKs) play a diverse role in cell growth and 
differentiation during normal physiologic responses and in oncogenic transformation 
and tumor progression. These cell surface receptors transmit extracellular signals by 
activation of intrinsic kinase activity, which phosphorylates cytoplasmic domains of 
clustered receptor complexes and other target proteins, thus initiating a cascade of 
signaling events that modulate cellular responses. Mutations leading to production of 
constitutively active receptors or overexpression of a normal receptor results in 
increased kinase activity and oncogenic transformation. Consequently, small 
molecule inhibitors of receptor tyrosine kinases are proving to be efficacious in the 
clinic for several cancer types [reviewed in (86)]. 
 Eph receptors represent the largest family of receptor tyrosine kinases in the 
genome, consisting at least 16 receptors that interact with nine membrane-bound 
ephrin ligands [reviewed in (3, 13)]. They can be further divided into two groups, 
class A and B, based on sequence homology and binding affinity (87). Class A Eph 
receptors interact with multiple ligands of the ephrin-A family, a group of glycosyl-
phosphoatidylinositol (GPI)-linked membrane proteins, while class B Eph receptors 
binds to ephrin-B ligands, a family of transmembrane proteins. Binding of Eph 
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receptors to their ligands induces receptor clustering, activation of kinase activity, and 
subsequent trans-phosphorylation of the cytoplasmic domains, creating docking sites 
for a number of signaling proteins [reviewed in (88, 89)]. In addition to kinase-
dependent signaling, binding of certain members of the Eph family, such as EphA8 or 
EphB3, can also trigger kinase-independent signaling (80, 90). In contrast to other 
families of receptor tyrosine kinases, Eph receptor signaling does not promote 
proliferation but leads to regulation of cell–cell, cell–matrix adhesion and cell 
motility. 
 The Eph family RTKs and their ligands initially attracted interest as modulators of 
axonal guidance, angiogenesis, and embryonic patterning during development 
[reviewed in (88, 91)]. It is now clear that the Eph molecules also play a role in adult 
tissues under physiological conditions and in disease states such as cancer. Eph RTKs 
and their ligands, the ephrins, are frequently overexpressed in different types of 
cancer [reviewed in (13, 92, 93)]. One family member in particular, the EphA2 
receptor, has been linked to breast, prostate, lung and colon cancer, as well as 
melanoma (22, 94). In cell lines, EphA2 overexpression is associated with increased 
cell growth in soft agar (30), increased invasion into Matrigel (30, 38), increased 
resistance to anoikis (38), and increased tumor growth when these cells were 
implanted into nude mice (30). Conversely, inhibition of EphA2 expression in tumor 
cells by siRNA (38) or induction of EphA2 degradation by ligand- or activating 
antibody-induced endocytosis (66) resulted in decreased cell invasion into matrigel, 
increased anoikis, and inhibition of tumor growth in vivo (95, 96). However, despite 
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the strong correlation of EphA2 receptor expression with malignant phenotypes, the 
mechanisms by which EphA2 contributes to tumor cell malignancy are far from clear. 
 One important mechanistic question is whether EphA2 receptor phosphorylation 
and kinase activity play a role in malignant transformation/progression. In certain 
tumor cell lines, EphA2 receptor is underphosphorylated (40). However, despite the 
low phosphorylation level, EphA2 kinase activity was not affected (40). Ligand-
induced EphA2 phosphorylation induces receptor endocytosis and degradation, 
reducing malignant behavior of the cells and tumor growth in vivo (66). Such 
evidence supports the idea that EphA2 receptor phosphorylation is not necessary to 
confer kinase activity and tumorigenicity, but leaves question unanswered as to 
whether kinase activity is required for tumor malignancy. Other data have emerged 
showing that EphA2 receptor phosphorylation may be important in conferring 
oncogenic potential. Dobrzanski et al. (2004) observed high EphA2 receptor 
phosphorylation levels in xenografts of ASPC-1, U87MG, and SVP cell lines (97). 
Ogawa also reported EphA2 receptor phosphorylation in human mammary carcinoma 
xenography (22). In addition, studies using the 4T1 model of tumorigenesis have 
found that blocking EphA2 receptor activation through EphA2-Fc results in a 
decrease in phosphorylation that was concurrent with decreased tumor volume (23, 
39, 97). 
 To directly test the role of EphA2 receptor phosphorylation/kinase activity, we 
overexpressed EphA2 variants, either lacking the cytoplasmic domain or carrying a 
point mutation that abolishes its kinase activity, in breast cancer cells. Expression of 
these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and 
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increased tumor apoptosis in primary tumors, and significantly reduced the number of 
lung metastases. These data suggest that phosphorylation and kinase activity of the 
EphA2 receptor, at least in part, contributes to tumor malignancy. 
 
Results 
 
EphA2 receptor phosphorylation in tumor cells is regulated by cell density  
 Prior studies have shown that EphA2 receptors are under-phosphorylated in 
certain breast tumor cell lines (40) but phosphorylated in other tumor cells (97).  As 
4T1 tumor cells express both endogenous ephrin-A1 ligand and EphA2 receptor (23), 
we determined whether EphA2 receptors are tyrosine phosphorylated by engaging 
endogenous ephrin-As in a cell-cell contact-dependent manner, and whether the level 
of EphA2 tyrosine phosphorylation can be further elevated by exogenous ephrin-A1 
ligand.  We used two independent approaches to address this issue.  First, cells were 
plated onto 10-cm dishes with 100%, 50%, or 25% confluency in the presence or 
absence of 1 μg/ml exogenous ephrin-A1 ligand for 15 minutes.  Cell lysates were 
immunoprecipitated by anti-EphA2 and blotted for phosphotyrosine level.  As shown 
in Figure 4A, phosphorylation of EphA2 receptor is up-regulated with increased cell 
density at basal level, and phosphorylation of EphA2 is further enhanced by 
exogenous ephrin-A1 ligand stimulation.  In a second approach, identical numbers of 
4T1 tumor cells were plated on culture dishes of different surface areas (3.5 cm, 6 cm, 
and 10 cm) so that cell density decreases with the increase of dish size (Fig. 4B).  In  
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Figure 4.  Cell density regulates the phosphorylation of EphA2 receptors.  (A) 
Metastatic 4T1 mammary carcinoma cells were plated onto 10-cm dish with 100%, 
50%, or 25% confluency.  (B) Identical numbers (5 x 105) of 4T1 cells were plated on 
culture dishes of different surface areas (3.5 cm, 6 cm, and 10 cm).  Cells were 
serum-starved overnight and stimulated with 1 μg/ml of ephrin-A1 ligand for 15 
minutes.  EphA2 proteins were immunoprecipitated from cell lysates and blotted for 
tyrosine phosphorylation and for total EphA2.  Relative levels of pEphA2 and total 
EphA2 were quantified by densitometry using Scion image 1.62 software analysis.  
3.5cm*, 5 dishes of 3.5 cm plate were pooled for western blot analysis. (C) Western 
blot analysis of ephrin-A1 ligand. 
 
p<0.01 
* * *
p<0.05 
*
* 
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cells on 10 cm dish where there is no significant level of cell-cell contact, EphA2 is 
barely activated in the absence of ligands, yet became tyrosine phosphorylated upon 
exposure to exogenous ephrin-A1.  With increasing cell density (6 cm and 3.5 cm), 
EphA2 receptor expression level gradually decreases. However, when adjusted to 
similar level of EphA2 expression by combining cells in 5 dishes of 3.5 cm  plate, the 
EphA2 tyrosine phosphorylation level increases in high-density cell culture (Fig. 4B, 
3.5 cm*).  Ephrin-A1 levels did not change significantly with different cell density 
(Fig. 4C).  These results revealed that high cell density up-regulates basal level of 
tyrosine phosphorylation of EphA2 receptor and phosphorylation of EphA2 receptor 
can be further increased by stimulation of exogenous ephrin-A1 ligand. 
 
Signaling-defective forms of EphA2 mutants inhibit 4T1 mammary tumor 
progression in vivo 
 
 To test directly the role of EphA2 receptor phosphorylation/kinase activity, we 
generated EphA2 mutants that were either lacking the cytoplasmic domain (ΔC) or 
carrying a D738N point mutation (W42) (Figure 5A).  W42 mutation is analogous to 
a spontaneously occuring loss of function point mutation identified in the W42 
dominant negative allele of the c-kit receptor tyrosine kinase (98, 99) that serves as a 
dominant negative mutation for other RTKs in cell culture models (100).  EphA2-
deficient cells were infected with LZRS retrovirus expressing wild-type EphA2 
receptor (WT), W42 mutant, or vector control and kinase activity of each receptor 
variant was determined by in vitro kinase assay.  As shown in Figure 5B, EphA2-
deficient cells have no detectable level of kinase activity.  While overexpression of 
wild-type EphA2 receptor restored kinase activity, overexpression of W42 mutant  
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Figure 5.  Signaling defective EphA2 mutants act in a dominant negative fashion.  (A) 
A diagram of domain structures of wild-type and mutant forms of EphA2 receptor.  
(B) EphA2-deficient endothelial cells were infected with retrovirus LZRS expressing 
wild-type EphA2, W42 mutant, or vector control.  Cells were serum-starved 
overnight and stimulated with 1 μg/ml of ephrin-A1 ligand for 15 minutes.  EphA2 
proteins were immunoprecipitated and subjected to in vitro kinase assay.  W42 
mutant is defective in kinase activity.  (C) 4T1 clones expressing wild-type and 
mutant forms of EphA2 receptors were subject to immunoprecipitation /western blot 
analysis for EphA2 and phosphorylated tyrosine as in Figure 1.  EphA2-ΔC and W42 
mutants act in a dominant negative fashion to inhibit endogenous EphA2 receptor 
phosphorylation in response to ephrin-A1 ligand.  (D) In vitro analyses of 
proliferation and apoptosis in 4T1 cells expressing wild-type or mutant forms of 
EphA2.  Cell proliferation and apoptosis were assessed by expression of proliferating 
cell nuclear antigen (PCNA) and activated caspase-3, respectively.  There is no 
significant difference in proliferation or apoptosis between 4T1 expression wildtype 
or mutant EphA2 proteins. 
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protein failed to confer kinase activity in EphA2-deficient cells, suggesting that W42 
is a kinase-dead mutant.   
 Multiple 4T1 clones expressing either wild-type EphA2 receptor (WT), signaling-
defective mutant forms of EphA2, ΔC or W42, or control vector were generated.  As 
shown in Figure 5C, compared to vector control, overexpression of wild-type EphA2 
leads to a constitutive phosphorylation of the receptor.  In contrast, overexpression of 
mutant ΔC or W42 forms of EphA2 significantly inhibited ligand-induced receptor 
phosphorylation, suggesting that these mutants act in a dominant negative fashion to 
inhibit endogenous receptor signaling.  As expected, transfected wild-type or mutant 
EphA2 proteins localized to the cell surface of culture cells (data not shown).  When 
cultured in vitro, there are no significant changes in either cell proliferation or 
apoptosis among multiple 4T1 clones expressing wild-type or signaling-defective 
mutant forms of EphA2 receptor (Fig. 5D).  
 To assess whether EphA2 function in tumor growth and metastasis is kinase-
dependent, 4T1 clones expressing either wild-type or mutant EphA2 proteins 
(100,000 cells) were injected in the mammary fat pad of syngeneic Balb/C recipient 
mice, and tumors were harvested one week later for analysis.  While tumors 
expressing wild-type EphA2 have similar tumor volume as control tumors, tumors 
expressing either ΔC or W42 mutants (Figure 6A) have a much smaller tumor volume 
(p<0.01, ANOVA; p<0.01, unpaired student's t test, ΔC-1, ΔC-2, or W42 versus 
Vector, WT-1, or WT-2).  We next determined whether decreased tumor volume in 
tumors expressing EphA2 signaling-defective mutants is due to decreased 
proliferation or increased apoptosis.  Tumor growth was assessed by quantifying 
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nuclear expression of proliferating cell nuclear antigen (PCNA), a marker for actively 
dividing cells; and cell death was determined by in situ TUNEL stain in tumor 
sections.  As shown in Figure 6B, compared to wild-type EphA2 tumors, there is an 
approximately two-fold increase in TUNEL positive nuclei in tumors expressing 
signaling-defective EphA2 mutants (p<0.01, ANOVA; p<0.01 Student's t test.  
Vector or WT versus ΔC-1, ΔC-2, or W42).  However, there is no significant 
difference in tumor cell proliferation between tumors expressing wild-type EphA2 
and those expressing EphA2 mutants (data not shown), consistent with studies 
suggesting that Eph RTKs do not promote proliferation directly (23).  Taken together, 
these data suggest that blockade of EphA2 forward signaling in tumor cells by 
signaling-defective EphA2 mutants inhibits tumor progression by promoting tumor 
cell apoptosis.  
 
Signaling-defective forms of EphA2 mutants inhibit lung metastasis 
 To determine whether blocking of EphA2 signaling in tumor cells could suppress 
metastatic progression, 10,000 4T1 cells expressing either wild-type or mutant forms 
of EphA2 proteins were administered intravenously into Balb/C recipient mice.  
Twelve days after injection, lungs were harvested, fixed, and processed for 
histological analyses.  Gross examination revealed numerous lung surface metastases 
in mice injected with 4T1 cells expressing wild-type EphA2, compared to 4T1 cells 
containing vector alone (Figure 7A, top panels).  In contrast, there were significantly 
lower numbers of visible lung surface metastases in mice injected with 4T1 cells 
expressing signaling-defective EphA2 mutants (Figure 7A, bottom panels), compared  
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Figure 6.  Dominant negative EphA2 mutants inhibit 4T1 mammary tumor 
progression in vivo.  (A) A hundred thousand 4T1 cells or 4T1 cells expressing wild-
type or mutant EphA2 proteins were orthotopically transplanted into the mammary 
gland of syngeneic Balb/C female mice.  Tumors were harvested one week after 
transplantation and tumor volume was measured as described in the Materials and 
Methods.  Tumors expressing ΔC or W42 EphA2 mutants exhibit significantly 
smaller tumor volume than those of vector or WT control tumors. (B) Tumor paraffin 
sections were subjected to TUNEL assay to evaluate the level of apoptosis.  Arrows 
indicate TUNEL positive nuclei.  A significant increase in apoptosis was observed in 
tumors expressing ΔC or W42 EphA2 mutants. 
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to 4T1 cells expressing wild-type EphA2.  Histological examination of 
hematoxylin/eosin-stained lung sections revealed numerous large pulmonary 
metastases in lungs from mice harboring wild-type EphA2 tumors, while only small 
avascular metastases could be seen in lungs from mice harboring either ΔC-EphA2 or 
W42-EphA2 tumors (data not shown).  Comparison of tumor metastasis by counting 
the lung surface metastases confirmed that mice injected with 4T1/WT-EphA2 cells 
carried a significantly greater metastatic burden than mice injected with cells 
expressing either vector control, ΔC, or W42 (Figure 7B) (p<0.01, ANOVA; p<0.05, 
unpaired student's t test, ΔC-1, ΔC-2, or W42 versus WT-1, or WT-2).  These results 
suggest that signaling-defective forms of EphA2 mutants inhibit the colonization of 
tumor cells in the lung.   
 To determine whether signaling-defective forms of EphA2 mutants could also 
inhibit spontaneous metastases, 500,000 parental 4T1 cells or 4T1 cells expressing 
wild-type or mutant EphA2 receptors were implanted into mammary gland fat pads of 
recipient Balb/C females and tumors were grown for 21 days to permit spontaneous 
lung metastases.  Consistent with data derived from 1-week tumors, we observed 
significantly decreased tumor volume in tumors expressing ΔC or W42 at 3 week 
(Figure 7A) (p<0.01, ANOVA; p<0.01, unpaired student's t test, ΔC-1, or W42 versus 
4T1, or WT-1).  The number of surface lung lesions in EphA2 signaling-defective 
tumor recipients was also reduced compared to controls (data not shown).  
Quantification of total lesions in cleared lungs by staining with hematoxylin revealed 
a significant decrease in EphA2-deficient tumor recipients relative to controls (Figure 
8B) (p<0.01, ANOVA; p<0.01, unpaired student's t test, ΔC-1, or W42 versus WT-1).   
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Figure 7.  Decreased lung metastasis in 4T1 cells expressing ΔC or W42 EphA2 
mutants.  Ten thousand 4T1 cells expressing wild-type or mutant EphA2 receptors, or 
vector control were administered intravenously and lungs were harvested 12 days 
later.  (A) Gross examination of lungs from mice injected with 4T1 cells expressing 
ΔC or W42 mutants revealed fewer surface lesions than in those collected from mice 
injected with 4T1 cells expressing wild-type EphA2 or vector control.  Arrows 
indicate surface metastatic lesions.  (B) Surface metastases were enumerated, and a 
significantly lower number of lesions was detected in lungs from mice injected with 
4T1 cells expressing ΔC or W42 mutants relative to controls. 
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These data demonstrate that EphA2 signaling-defective mutants inhibit tumor 
metastasis in vivo. 
 
Signaling-defective EphA2 mutants do not affect tumor angiogenesis but inhibit 
tumor cell motility   
 
 It has become increasing clear that multiple factors could influence tumor 
metastasis, including tumor angiogenesis and increased tumor cell motility.  As 
EphA2 receptor and ephrin-A ligands were previously shown to be involved in tumor 
neovascularization (23, 39, 97), we first determined the abundance of microvessels in 
tumors expressing either wild-type or mutant EphA2 receptors.  No significant 
difference of tumor microvascular density was observed between tumors expressing 
wild-type and mutant EphA2 receptors (data not shown), suggesting that tumor 
angiogenesis is not a determining factor for decreased tumor metastasis in tumors 
expressing mutant EphA2 receptors.   
 Next we determined the ability of cells to migrate, as cell motility contributes to 
tumor invasion and metastasis.  4T1 cells expressing WT, W42, ΔC, or vector control 
were grown to confluency and monolayer of cells was then scratched with a pipette 
tip.  As shown in Figure 9A, the wound closing process was significantly retarded in 
4T1 cells expressing mutant W42 or ΔC receptor, compared to those expressing WT 
receptor, vector control, or parental 4T1 cells, suggesting that blocking of EphA2 
receptor signaling inhibits tumor cell motility.  As dynamic regulation of the actin 
cytoskeleton is critical in cell migration and Rho family GTPases are known to be key 
regulators of this process [reviewed in (101-103)], we examined the level of activated 
Rho family GTPases in 4T1 clones expressing wild-type or mutant EphA2 by GST- 
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Figure 8.  EphA2-ΔC or W42 mutants inhibit spontaneous lung metastasis.  Five 
hundred thousand tumor cells were orthotopically implanted into mammary gland of 
syngeneic recipient Balb/C female mice.  Primary breast tumors and lungs were 
collected 21 days later.  (A) Tumors expressing ΔC or W42 mutants exhibit 
significantly smaller tumor volume than those of 4T1 parental or wild-type control 
tumors. (B) Quantification of total lung metastases revealed a significant decrease in 
lung lesions from mice harboring tumors expressing ΔC or W42 mutants relative to 
controls. 
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Rhotekin or GST-PAK pull-down assays.  As shown in Figure 9B, there is no 
significant difference in Rac activity between cells expressing wildtype EphA2 and 
those expressing mutant EphA2 proteins, although Rac activity appears to increase in 
cells expressing EphA2 proteins for unknown reasons.  In contrast, ephrin-A1 
stimulation induced RhoA activation within 2.5 minutes in both vector-transfected 
4T1 cells and 4T1 cells expressing WT-EphA2.  RhoA activation was undetectable in 
cells expressing W42-EphA2 or ΔC-EphA2 mutant proteins.  Thus, it appears that the 
changes in RhoA activity is more relevant to phenotypes we observed.  Taken 
together, these data suggest W42-EphA2 or ΔC-EphA2 mutants may suppress tumor 
cell migration through inhibition of RhoA activation. 
 
Discussion 
 Classic oncogenic transformation by receptor tyrosine kinases and their growth 
factor ligands involves elevated levels of receptor autophosphorylation and tyrosine 
kinase activity.  In fact, an abnormally high level of tyrosine kinase activity is the 
major determinant of the oncogenic potential of an RTK, as is the case for ErbB2/Neu 
(104).  However, it is not clear whether receptor autophosphorylation and kinase 
activity is required for EphA2 receptor-mediated oncogenic transformation or in the 
development of metastatic potential.  siRNA knock down of EphA2 receptor tyrosine 
kinase expression in pancreatic cancer cells inhibits tumor growth and metastasis 
(38), but this study did not address whether the kinase activity is required for tumor 
malignancy. Soluble EphA2-Fc receptor can effectively inhibit EphA2 receptor 
phosphorylation and tumor growth and metastasis in vivo (23, 39, 97).  While this  
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Figure 9.  Reduced cell migration in 4T1 cells expressing ΔC or W42 EphA2 mutants.  
Cells were cultured in 12-well plates until confluency.  The monolayer was wounded 
with a fine pipette tip to create a circular wound.  (A) Pictures were taken at 2, 4, 6, 8 
and 24 hours after wounding.   Residual "wound" areas were measured and quantified 
by Scion Image software.   Percentage of remaining wounded area in 4T1 cells 
expressing ΔC or W42 EphA2 mutants at 24 hours is significantly greater than 
controls, indicating reduced migration.  (B) Active GTP-bound forms of RhoA and 
Rac1 were analyzed by Rhotekin-RBD or Pak-PBD pull-down followed by 
immunoblot in lysates from 4T1 cells overexpressing wild-type or mutant forms of 
EphA2 receptors or vector control.  Expression of ΔC or W42 EphA2 mutants 
blocked basal and ephrin-A1-induced RhoA activation (p<0.01) but had no 
significant effect on Rac1 activation.  
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study supported the notion that EphA2 receptor phosphorylation/activation is required 
for tumor progression, these in vivo studies cannot differentiate the effect of soluble 
EphA2-Fc receptor on tumor cells from other cell types in the tumor 
microenvironment.  Finally, Zantak et al showed that EphA2 receptor is not 
phosphorylated in some human breast cancer cell lines, although the 
unphosphorylated receptor still has kinase activity (40).  Overexpression of EphA2 
receptor in the immortalized breast epithelial cell line MCF10A induces oncogenic 
transformation, but again the overexpressed EphA2 receptor is not phosphorylated 
(30).  These data argue for a phosphorylation-independent role of EphA2 in 
oncogenic transformation.  In this report, we found that EphA2 level and 
phosphorylation status are cell-density dependent in culture.  Inhibition of receptor 
phosphorylation by EphA2 mutants that either contain a cytoplasmic deletion (ΔC) or 
a point mutation rendering "kinase-dead" (W42) suppressed the activity of RhoA 
GTPase and tumor cell motility.  Furthermore, blocking of EphA2 receptor signaling 
by ΔC or W42 mutants inhibited tumor growth and lung metastasis in vivo.  Taken 
together, our results suggest a kinase-dependent role of EphA2 in tumor progression.   
 In addition to a kinase-dependent role of EphA2 in tumor progression, EphA2 
may also have kinase-independent functions.  Genetic studies in vivo have shown that 
Eph receptors have both kinase-dependent and kinase-independent functions (105-
108).  In addition, some Eph receptors either have kinase-deficient variant forms 
generated by alternative splicing (EphA6, 7, and B1) (109) or have kinase domains 
with defective catalytic activity (EphB6 and A10) (110, 111).  Activation of EphA8 
induce extracellular matrix adhesion through a PI3Kγ-mediated regulation of integrin 
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activity in a kinase-independent manner (80).  More recently, Miao et al showed that 
inhibition of integrin-mediated cell adhesion but not directional cell migration 
requires EphB3 tyrosine kinase activity (90).  Finally, the phenotypes of ΔC tumors 
are more severe than W42 tumors, suggesting an additional function of cytoplasmic 
domain of EphA2 receptor independent of its kinase activity.   
 Aside from EphA2 receptor, the expression of EphB4 receptor is also elevated in 
breast carcinomas with a high grade of malignancy (112).  In transgenic mouse 
models of mammary carcinogenesis, overexpression of EphB4 in mammary epithelial 
cells leads to accelerated tumor growth and metastatic progression caused by the Neu 
oncogene (113).  Interestingly, tumor promotion effects of the EphB4 overexpression 
may not be due exclusively to EphB4 forward signaling, as overexpression of a 
EphB4 cytoplasmic trunction mutant, EphB4ΔC-EGFP, also increases tumor growth 
(114).  The tumor growth promotion effects of EphB4ΔC-EGFP are apparently due to 
reverse signaling through ephrin-B2 via enhanced tumor angiogenesis (114).  
Although there is precedence for reverse signaling through class A ephrin ligands 
(115-117), we do not think the tumor suppression effect of ΔC-EphA2 or W42-
EphA2 is due to reverse signaling because WT-EphA2 retains the capability to signal 
through ephrin-As but have the opposite biologic outcome.   As both WT-EphA2 and 
signaling-defective EphA2 mutants are specifically expressed in the tumor cells, we 
believe the reduced tumor volume and decreased metastasis in ΔC-EphA2 or W42-
EphA2 tumors is due to defective forward signaling in tumor cells. 
 What is the mechanism of EphA2 signaling-defective mutant-mediated inhibition 
of tumor progression in vivo?  Inhibition of primary tumor growth could result from 
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suppression of tumor cell proliferation or enhancement of tumor cell death directly, or 
reduction of tumor blood vessels indirectly.   As we did not observe any changes in 
tumor cell proliferation or tumor vessel density, increased apoptosis is likely to play a 
major role in diminishing tumor volume in primary tumors expressing EphA2 
signaling-defective mutant proteins.  It is interesting to note that while program cell 
death is increased in tumors expressing signaling mutant forms of EphA2 receptor 
(Fig. 6B), we did not observe a significant change between wildtype and mutant 
forms of EphA2 in apoptosis in cultured cells under serum starvation in vitro (Fig. 
5D).  As tumor in vivo interacts with its complex microenvironment, apoptosis can 
occur in response to stimuli (e.g. Fas ligand) other than cytokine/nutrient deprivation.  
Further experiments will be needed to dissect the role of EphA2 receptor in cell 
survival in vivo.   
 Tumor metastasis is a complex multi-step process involving tumor cell invasion, 
intravasation, survival in the circulation, extravasation, local migration and 
colonization of secondary organs.  Decreased cell motility and increased apoptosis in 
tumors expressing EphA2 signaling-defective mutant proteins could affect multiple 
steps of the metastatic process, leading to decreased metastatic lesions in vivo.  
Comparison of the results from experimental metastasis with those from spontaneous 
metastasis suggests that in addition to a possible role in tumor cell invasion and 
intravasation, EphA2 receptor is also essential in later steps of metastasis involving 
colonization of lung tissue.  In addition to the effect of EphA2 signaling on 
metastasis, recent data from multiple laboratories showed that the level of EphA2 
expression correlates with the degree of tumor malignancy and metastasis (33, 36, 
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118), suggesting high level of EphA2 protein promotes metastasis.  In support of this 
hypothesis, we observed that mice received 4T1 expressing wildtype EphA2 
exhibited elevated number of lung metastases compared to those received parental 
4T1 cells or 4T1 vector controls (Fig. 7B and 8B).   Although there is no significant 
difference in cell migration between WT-1 and parental 4T1 cells, it is conceivable 
that WT-1 has advantage over parental 4T1 in other steps of metastasis.  For example, 
EphA2 has been shown to regulate the expression of MMP-2 (96).  Thus, in principle, 
one mechanism by which elevated EphA2 receptor could promote tumor cell invasion 
and colonization is via an MMP-dependent mechanism. 
 Cell migration can be divided into separate steps: lamellipodium extension, 
formation of new adhesions, cell body contraction and tail detachment.  Rho family 
small GTPases are well-established as mediators in these steps: Rac 1 is required for 
lamellipodium extension and formation of new adhesion, while RhoA is primarily 
involved in stress fiber formation and cell body contraction [reviewed in (103)].   In 
general, Rac1 activation promotes cell migration.  However, RhoA activation can 
either inhibit or promote cell migration depending on cell types and experimental 
conditions(103).  In less adherent cells such as macrophages, neutrophils and various 
cancer cell lines, RhoA activity has been correlated to cell polarization and migration 
(119).  Under our experimental condition, we did not observe a significant decrease in 
Rac1 activity.  Rather, a dramatic inhibition of RhoA activity is seen in tumor cells 
expressing EphA2 signaling-defective mutants.  As 4T1 cells are very malignant 
metastatic cancer cells, activation of RhoA in this cell type may resemble to that of 
non-adherent cells to promote cell migration.  This hypothesis is consistent with the 
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fact that elevated expression of RhoA has been correlated with advanced tumor stage 
or enhanced metastasis in tumors, including breast cancer, melanomas, pancreatic 
ductal adenocarcinoma and testicular germ cell tumors (120).   
 Because EphA2 receptor is frequently overexpressed in human cancers and the 
level of EphA2 expression has been correlated with tumor malignancy, therapeutic 
strategies are currently being developed to inhibit EphA2 in cancer.  These includes 
down-regulation of EphA2 expression by siRNA (38), activating antibodies or ligand 
mimetic peptides to induce EphA2 endocytosis and degradation (121, 122), or 
blocking EphA2 receptor activation by soluble EphA-Fc receptor (23, 39, 97).  This 
study provides a mechanism for effectiveness of soluble EphA-Fc receptor and lays 
foundation for future development of EphA2-specific kinase inhibitors in cancer 
therapeutics. 
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CHAPTER IV 
OVEREXPRESSION OF EPHA2 RECEPTOR DESTABILIZES ADHERENS 
JUNCTIONS VIA A RHOA-DEPENDENT MECHANISM 
 
 
Introduction 
 
 Protein tyrosine phosphorylation is a powerful signal that regulates cell 
proliferation, cell invasion, and cell migration.  Mutation, gene amplification, or 
aberrant regulation of protein tyrosine kinase has been linked to tumor initiation and 
progression.  Specific tyrosine kinase inhibitors, such as inhibitors of the Her-2/Neu 
receptor and EGFR, have been developed for cancer therapeutics with varying 
degrees of success. While exciting in their clinical effectiveness, these inhibitors are 
only suitable for treating a small subset of cancer types.  The hope remains that other 
receptor tyrosine kinases will be identified and that their inhibition will have broader 
efficacy in cancer treatment.   
 A new family of receptor tyrosine kinases, the Eph family, plays a critical role in 
cancer.  Originally discovered as modulators of axonal guidance and embryonic 
patterning during development, subsequent studies have shown that many Eph 
receptors are overexpressed in a large number of cancers (3, 81).  One family member 
in particular, the EphA2 receptor, has been linked to breast cancer, prostate cancer, 
lung cancer, ovarian and cervical cancer, esophageal and colorectal cancer, as well as 
malignant melanoma (92).  Furthermore, the level of EphA2 receptor expressed on 
tumor cells correlates with the degree of tumor malignancy (123).  Overexpression of 
the EphA2 receptor in MCF-10A cells is associated with increased cell growth in soft 
 54
agar and increased tumor growth when these cells were implanted into nude mice 
(30).  However, despite the strong correlation of EphA2 receptor expression with 
malignant phenotypes, the mechanisms by which EphA2 contributes to tumor cell 
malignancy are not completely understood.   
 One hallmark of malignancy in tumor cells is the loss of cell-cell adhesion. In 
non-malignant circumstaces, cell-cell adhesion connects epithelial cells in their 
normal polarized position.  In mammals, adhesion between epithelial cells is 
generally mediated by three types of junctions: tight junctions, adherens junctions, 
and desmosomes.  Adherens junctions are cadherin-dependent adhesive structures 
that are intimately linked to the cytoskeleton.  The extracellular domain of classical 
cadherins mediates calcium-dependent homophilic interactions, whereas the 
intracellular domain interacts with several catenins. In general, the cadherin-bound 
catenins function to either anchor the adhesion complex to the actin cytoskeleton (β- 
and α-catenin) or regulate the cadherin stability at the junction (p120 catenin).  
Cadherins and their associating catenins are collectively known as the cadherin 
complex. The stability of the epithelial cadherin, E-cadherin, and its associated 
complex dictates both the polarity and the motility of epithelial cells (124).  Several 
studies have shown that the loss of E-cadherin down-regulates EphA2 receptor levels 
and induces EphA2 mis-localization in tumor cells and mouse embryonic stem cells 
(40, 63).  Likewise, VE-cadherin, another type of cadherin, appears to regulate 
EphA2 localization in melanoma cells that undergo vascular mimicry (125).  
However, the effect of EphA2 overexpression on adherens junctions remains unclear. 
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 Cell-cell adhesion is regulated by multiple mechanisms.  Rho family of GTPases 
have been increasingly recognized as key players in regulation of adherens junction 
[reviewed in (120, 124, 126)].  Rho proteins are small GTPases that cycle between an 
active, GTP-bound, conformation and an inactive, GDP-bound conformation.  In 
response to extracellular cues through cell surface receptor, Rho proteins can be 
activated by guanine nucleotide exchange factor (GEF) or inactivated by GTPase 
activating protein (GAP).  Multiple Eph receptors have been shown to modulate Rho 
family GTPase activity [reviewed in (89)].  EphA2 receptor activation leads to 
elevation of GTP-Rac1 via Vav GEFs in vascular endothelial cells to regulate 
angiogenesis (25, 56).  In epithelial and tumor cells, stimulation of EphA2 receptor 
induces activation of RhoA GTPase and affects cell migration (127, 128). 
 In addition to activation of Rho family GTPases, EphA receptors have been 
shown to both regulate low molecular weight phosphotyrosine phosphatase (LMW-
PTP) activity and serve as substrates for the same phosphatase.  Park S. showed that 
the EphA8 receptor phosphorylates and activates LMW-PTP in vitro (129).   
Conversely, LMW-PTP negatively regulates EphA receptors by dephosphorylation of 
EphA2 and EphA8 receptors (68, 71, 129).  Another substrate of the LMW-PTP is the 
p190RhoGAP.  In fibroblasts, LMW-PTP regulates adherens junction stability by 
modulating phosphorylation levels of p190RhoGAP (130).  However, the role of 
LMW-PTP in regulating receptor tyrosine kinases and/or cell-cell adhesion remains 
to be determined in epithelial cells. 
 To determine whether the EphA2 receptor can regulate adherens junctions, we 
expressed wild-type and mutant EphA2 in the immortalized, non-transformed MCF-
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10A breast epithelial cell line.  We found that overexpression of wild-type EphA2 de-
stabilizes adherens junctions.  Interestingly, EphA2 overexpression does not affect 
overall levels or phosphorylation status of E-cadherin, p120 catenin, β-catenin, and 
α-catenin, but appears to weaken the adherens junction by upregulating RhoA 
GTPase activity via p190 RhoGAP and LMW-PTP.  Thus, in addition to regulating 
tumor cell motility, the increased EphA2 receptor levels in tumors also promote 
destabilization of cell-cell adhesion through regulating RhoA GTPase activity. 
 
Results 
 
Overexpression of EphA2 receptor weakens cell-cell adhesion 
 Prior studies showed that loss of E-cadherin down-regulates EphA2 receptor 
levels and induces mis-localization of EphA2 in both tumor cells and mouse 
embryonic stem cells (40, 63, 125).  However, the reciprocal effect of EphA2 on 
adherens junction components remains unclear.  Because EphA2 levels are often 
elevated in tumor cells [reviewed in (92)], we studied the effects of overexpression of 
EphA2 receptor tyrosine kinase in the immortalized non-transformed MCF-10A 
breast epithelial cell line.  MCF-10A cells were infected with LZRS retrovirus 
overexpressing moderate levels of either full length, wild type EphA2-IRES-GFP or 
an EphA2 cytoplasmic truncation mutant, ΔC-IRES-GFP.  Pools of transduced cells 
were FACS sorted for comparable levels of EphA2 receptor expression and subjected 
to assays that measure adhesion strength and stability.   
 To study the impact of increased EphA2 receptor levels on cell-cell adhesion, we 
first performed a hanging drop aggregation assay, an assay that was designed to 
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assess the strength of cell-cell adhesion without the influence of cellular adhesion to 
the plate.  As shown in Figure 10A, A431 cells expressing wild-type E-cadherin 
induced tightly compacted cell aggregates that could not be dissociated by shear 
force.  In contrast, the control A431D cells, which do not express E-cadherin, 
exhibited loose association and immediate separation of cells when subjected to shear 
force.  MCF-10A cells grown in hanging drop suspension culture do not form 
compact cellular masses as A431 cells, but they do form a cell spheroid structure that 
was resistant to shear force separation.  Stimulation of ephrin-A1, however, resulted 
in cell-cell dissociation in MCF10A spheroids.  While vector transduced MCF-10A 
cells behave similarly to parental MCF-10A, overexpression of wild-type EphA2 in 
MCF-10A cells greatly facilitated the dissociation of cells by shear force.  In contrast, 
MCF-10A cells expressing the EphA2ΔC mutant form a tightly compact cell spheroid 
that was resistant to dissociation (Fig 10B).  These results suggest that EphA2 
receptor signaling is required for regulating the strength of cell-cell adhesion. 
Overexpression of EphA2 does not affect the expression and phosphorylation of 
cadherin/catenin proteins nor the composition of adherens junction complexes 
 To dissect the mechanisms by which overexpression of EphA2 promote 
dissociation of cell-cell contacts, we examined whether the altered cell-cell adhesion 
mediated by EphA2 receptor activation involved modulation of the adherens junction 
complex.  We observed no alteration in E-cadherin protein levels in stable junctions 
from cells cultured to confluence, as judged either by western blot analysis (Fig. 11A) 
or immunofluorescence (Figure 11C-F).  Since EphA2 activation does not result in 
cadherin loss, we evaluated whether it could compromise cell adhesion by modulating 
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Figure 10.  EphA2 overexpression in MCF10A cells impairs cell-cell adhesion.  (A) 
A431, A431D, and MCF10A cells were subjected to a hanging drop aggregation 
assay, as described in Material & Methods.  A431D cells, which lack E-cadherin 
expression, exhibited a defect in cell-cell adhesion.  Ephrin-A1 stimulation also 
induced dissociation of MCF10A cells.  (B) MCF10A-EphA2, but not MCF10A-ΔC 
cells, exhibited decreased cell-cell adhesion.  (C) Western blot analysis of EphA2 and 
Myc-tagged mutant ΔC protein in MCF10A cells. 
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the composition of adherens junctional complexes.  Adherens junctions consist of E-
cadherin molecules, the cytoplasmic domains of which interact directly with p120 
catenin and β-catenin.  α-catenin interacts with E-cadherin indirectly through binding 
with β-catenin and links the adherens junction to the actin cytoskeleton.  Thus, any 
member of the catenin family could impact the adhesive capacity and association with 
the cytoskeleton (124, 131).  However, the levels of p120 catenin, β-catenin, and α-
catenin were not altered in MCF-10A/WT-EphA2 cells compared to the control cell 
lines (Fig. 11A).  When E-cadherin was immunoprecipitated from MCF-10A/WT-
EphA2 cells, the levels of associated catenins were likewise unaltered in these cells 
compared to the immunoprecipitations from the control cell lines (Fig. 11B).  Nor 
were tyrosine phosphorylation levels of cadherin/catenin protein significantly 
changed among parental MCF-10A, MCF-10A/EphA2, or MCF-10A/ΔC cells (Fig 
11G).  Together, these data suggest that EphA2 receptor activation alone is unable to 
initiate the disruption of adherens junctions.  However, as shown in Figure 10, 
overexpression of EphA2 weakens the strength of cell-cell adhesion and may 
accelerate dissociation of cells in a dynamic environment. 
Overexpression of EphA2 accelerates adherens junction disruption by 
decreasing the localization of E-cadherin at the adherens junction 
 To test whether EphA2 can accelerate the dissociation of cell-cell adhesion, we 
performed a calcium depletion assay.  Cells were cultured in low calcium medium 
and disappearance of cellular junctions was monitored by immunofluorescence with 
anti-E-cadherin.  The rate of junction dissociation was compared in cells expressing 
either wild-type or mutant EphA2 receptor.  As shown in Figure 12E, 8 hours after 
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Figure 11. Effects of EphA2 expression on level and phosphorylation of 
cadherin/catenin proteins and the composition of adherens junction complexes.  (A) 
Total levels of E-cadherin, p120 catenin, β-catenin, and α-catenin were assayed by 
western blot analysis.  No significant differences in expression of these proteins were 
detected in the respective cell types in the presence or absence of ephrin-A1 
stimulation. (B) Association of the catenin proteins to E-cadherin was assessed by co-
immunoprecipitation of p120 catenin, β-catenin, or α-catenin with E-cadherin.  The 
ability of these proteins to associate with E-cadherin was unchanged regardless of 
ephrin-A1 stimulation. (C-F) E-cadherin is localized at cell-cell junctions in confluent 
MCF10A, vector control, MCF10A-EphA2, or MCF10A-ΔC cells.  (G) Association 
of catenin proteins to E-cadherin was assayed by co-immunoprecipitation in the 
presence of normal or low calcium medium.  Tyrosine phosphorylation of 
cadherin/catenin proteins was determined by western blot analysis. 
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calcium depletion, E-cadherin localization was substantially reduced at the junction in 
cells expressing wild-type EphA2 receptor.  In contrast, MCF-10A expressing mutant 
EphA2ΔC still retained E-cadherin localization at levels similar to those observed in 
parental MCF-10A cells (Fig. 12F and 12D, respectively).  Reduced levels of E-
cadherin at cell-cell junctions could be due to a decrease in E-cadherin synthesis, an 
increase in degradation, a change in cellular localization, or a re-distribution on cell 
surface.   However, total levels of E-cadherin were not changed among parental 
MCF-10A, MCF-10A/EphA2, or MCF-10A/ΔC cells either in normal or low calcium 
medium (Fig 11G), indicating that expression or degradation of E-cadherin was not 
affected in these cells.  To determine whether reduced E-cadherin levels at cell-cell 
contact in MCF10A/EphA2 cells was due to internalization of E-cadherin molecule, 
we performed a biotinylation assay.  No significant alterations of E-cadherin 
internalization were observed, suggesting that expression of EphA2 did not affect E-
cadherin endocytosis (data not shown).  Taken together, these data suggest that 
EphA2-dependent destabilization of cell-cell adhesion is probably mediated by a re-
distribution of E-cadherin on the cell surface.  
RhoA activity is required for EphA2-mediated destabilization of cell-cell 
adhesion 
 Adherens junctions are regulated by multiple mechanisms.  In addition to 
regulation of cadherin/catenin protein levels, phosphorylation status, and composition 
of adherens junction complex, Rho family GTPases are known to modulate adherens 
junction stability.  As Eph family RTKs are often capable of activating Rho family
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Figure 12.  EphA2 overexpression destabilizes adherens junctions.  MCF10A cells 
were cultured in the presence of normal (A&C) or low calcium (B) media for 24 
hours.  Cells were subsequently fixed and stained for anti-E-cadherin (A&B) or 
secondary antibody alone (C).  MCF10A cells carrying LZRS control vector (D), 
LZRS-EphA2 (E), or LZRS-ΔC (F) were subjected to calcium depletion for 8 hours 
and stained for E-cadherin.  EphA2 overexpression destabilized adherens junctions, 
as E-cadherin was barely detectable in MCF10A-EphA2 cells (E). 
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GTPases (89), we investigated whether EphA2-induced destabilization of cell-cell 
adhesion is mediated by Rho proteins.  We have previously shown that ephrin-A1 
stimulation of 4T1 mammary tumor cells induced activation of RhoA GTPase (127).  
Accordingly, we used a Rhotekin pull-down assay to test whether RhoA GTPase is 
also activated by EphA2 receptor signaling in MCF-10A cells.  As shown in Figure 
13A, ephrin-A1 stimulation of MCF10A cells induced RhoA activation within 5 
minutes.  The basal levels of RhoA activity was elevated in cells expressing WT-
EphA2, but was diminished in cells expressing the ΔC-EphA2 mutation.  Although 
RhoA activity is often regulated by Rac (130), we did not observe significant changes 
in the level of activated Rac1 between cells expressing WT-EphA2 and cells 
expressing the ΔC-EphA2 mutant. 
 To test the functional role of EphA2-activated RhoA GTPase in cell-cell 
adhesion, we assessed the effect of inhibition of RhoA activity on cell adhesion.  Rho 
proteins can regulate adherens junctions by signaling through ROCK kinase (132).  
Therefore, we performed a calcium depletion assay in the presence of ROCK 
inhibitor Y-27632 to specifically block the actin-myosin contraction pathway.  As 
shown in Figure 13B and D, 8 hours after calcium depletion, E-cadherin was 
substantially reduced in cells expressing wild-type EphA2 receptor (Fig. 13D) 
relative to parental MCF10A (Fig. 13B).  However, inhibition of ROCK activity in 
EphA2 overexpressing cells (Fig. 13E) partially restored the expression of E-cadherin 
to a level similar to the expression in parental MCF-10A cells (Fig. 13B) and cells 
expressing the ΔC mutation (Fig. 13C). These data suggest that RhoA activity is 
required for EphA2-mediated destabilization of cell-cell adhesion.   
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 To investigate whether increased RhoA activation is sufficient to disrupt cell-cell 
adhesion in MCF10A and MCF10A-ΔC cells, these cells were transduced with 
control Ade-LacZ or a constitutively activated Rho mutant Ade-Rho (Q63L) (133, 
134).  As shown in Figure 13F and H, the MCF10A and MCF10A-ΔC cells infected 
with control viruses exhibited stable adherens junctions.  In contrast, expression of 
activated Rho in the MCF10A and MCF10A-ΔC (Fig. 13G and I) cells destabilized 
adherens junctions, consistent with the notion that activation of RhoA GTPase is 
sufficient to regulate the stability of cell-cell adhesion [reviewed in (120, 124, 126)].  
EphA2-dependent activation of RhoA is regulated by p190 RhoGAP   
 Rho GTPases cycle between an inactive, GDP-bound, conformation and an 
active, GTP-bound, conformation.  The Rho proteins can exchange nucleotide and 
hydrolyse GTP at slow rates in vitro, and these reactions are catalyzed by guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), 
respectively.  Recent studies showed that p190RhoGAP binds to p120-catenin and 
regulates cell-cell adhesion via inhibition of Rho activity (135).  To investigate 
whether EphA2-dependent activation of RhoA is regulated by GAP proteins, we 
measured the phosphorylation state of p190RhoGAP.  As shown in Figure 14A, 
tyrosine phosphorylation of p190RhoGAP in MCF-10A cells overexpressing the 
EphA2 ΔC mutant was significantly elevated, compared to cells overexpressing 
wildtype EphA2.   
 To assess the functional role of p190 RhoGAP in EphA2-dependent 
destabilization of adherens junctions, MCF-10A and MCF-10A-ΔC cells were 
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Figure 13.  EphA2 regulates adherens junction stability via modulation of RhoA activity.  
(A) Activated Rho and Rac GTPases in MCF10A, MCF10A-EphA2, or MCF10A-ΔC 
cells in response to ephrin-A1 stimulation were measured by GST-Rhotekin binding 
domain and GST-Pak binding domain pull-down assays, respectively.  Total levels of 
Rho and Rac proteins were assay by western blot analysis. * p<0.05. (B-E) MCF10A, 
MCF10A-ΔC, MCF10A-EphA2, or MCF10A-EphA2 treated with ROCK kinase 
inhibitor, Y27632, were subjected to calcium depletion for 8 hours, followed by detection 
of E-cadherin.  (F-I) MCF10A and MCF10A-ΔC cells expressing a constitutively active 
Rho (Q63L) or control β-galactosidase (LacZ) were assayed for adherens junction 
stability by calcium depletion assay.  (J) The expression and activity of Q63L in control 
and MCF10A-ΔC cells were confirmed by Rhotekin pull-down assays and western blot 
analysis. 
 66
transduced with LZRS retrovirus expressing wild type p190 or p190/30-1, a p190 
mutant that is defective in GTPase activating enzymatic activity.  As expected, in the 
MCF-10A and MCF-10A-ΔC cells, E-cadherin remains localized to cell-cell contacts 
even after calcium depletion of 8 hrs (Fig. 14B and E).  Expression of wild-type p190 
did not affect the localization of E-cadherin (Fig. 14C and F).  However, while 
overexpression of EphA2 resulted in loss of E-cadherin expression at cell-cell 
contacts (Fig. 14H), expression of wild-type p190 in these cells completely restored 
E-cadherin expression (Figure 14I).  Conversely, expression of the p190/30-1 in the 
MCF10A and MCF10A-ΔC cells resulted in a destabilization of the adherens 
junctions, as shown by loss of E-cadherin localization at the cell-cell contacts (Fig. 
14D and G).  These data suggest that EphA2 destabilizes the adherens junction by 
regulating p190 RhoGAP activity.  
 
LMW-PTP acts downstream of the EphA2 receptor to regulate p190 RhoGAP 
 Next, we wanted to determine how p190 RhoGAP is regulated by EphA2.  A 
plausible candidate is the ubiquitously expressed Low Molecular Weight Protein 
Tyrosine Phosphatase (LMW-PTP), because p190Rho-GAP has been shown to be a  
target of LMW-PTP (130, 136).  In addition, Eph receptors are known to recruit 
LMW-PTP upon receptor activation (40, 137).  To investigate whether LMW-PTP 
function can be regulated by EphA2 receptor, we first measured LMW-PTP 
phosphatase activity in MCF-10A-EphA2 and MCF-10A-ΔC cells using the synthetic 
substrate DiFMUP (138-140).  As shown in Figure 15A and B, LMW-PTP activity 
was significantly higher in MCF-10A-EphA2 cells than that in MCF-10A-ΔC cells.   
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Figure 14. EphA2 regulates adherens junction stability through p190 RhoGAP.  (A) 
p190 RhoGAP were immunoprecipitated from MCF10A, MCF10A-ΔC, or MCF10A-
EphA2 cell lysates and blotted for tyrosine phosphorylation.  Tyrosine 
phosphorylation of p190 was decreased in MCF10A-EphA2 cells. (B-I)  MCF10A, 
MCF10A-EphA2, and MCF10A-ΔC cells expressing p190 or the dominant negative 
p190 mutant, 30-1, were assayed for adherens junction stability by calcium depletion 
assay.  Expression of wild-type p190 rescued the adherens junctions in MCF10A-
EphA2 cells (I), whereas expression of 30-1 mutant destabilized cell-cell adhesion in 
parental MCF-10 cells and MCF10A-ΔC cells (D&G). 
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  To determine the mechanisms by which EphA2 regulates LMW-PTP activity, we 
investigated whether EphA2 affects LMW-PTP protein levels, phosphorylation states, 
or recruitment of LMW-PTP to EphA2 receptor.  Neither the total levels of LMW-
PTP protein nor the tyrosine phosphorylation state were affected by overexpression of 
EphA2 or inhibition of EphA2 signaling (data not shown).  However, higher levels of 
the interaction between EphA2 and LMW-PTP were detected in MCF-10A-EphA2 
cells (Fig. 15C), suggesting that EphA2 receptor recruits LMW-PTP.  We reasoned 
that if EphA2 is signaling through LMW-PTP to destabilize the adherens junctions, 
this phenotype should be rescued by overexpression of the phosphatase inactive 
mutant of LMW-PTP, C12S (141).  To test this possibility, MCF-10A-EphA2 cells 
were transduced with retrovirus expressing C12S and assayed for tyrosine 
phosphorylation of p190 RhoGAP and stability of the adherens junction.  Consistent 
with data shown in Figure 14A, p190 RhoGAP tyrosine phosphorylation is decreased 
in cells overexpressing EphA2, and expression of the dominant negative C12S mutant 
restores RhoGAP tyrosine phosphorylation levels (Fig 15D).  In  
addition, while MCF-10A-EphA2 cells transduced with control virus exhibited 
reduced E-cadherin staining at sites of cell-cell contact (Fig. 15E), expression of the 
LMW-PTP-C12S mutant stabilized the adherens junctions (Fig. 15F).  Taken 
together, these data suggest that LMW-PTP provides a molecular link between 
EphA2 receptor activation and the inhibition of p190 RhoGAP, leading to activation 
of Rho GTPase and destabilization of the adherens junctions. 
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Figure 15.  LMW-PTP interacts with EphA2 and regulates adherens junction stability.  
(A) LMW-PTP was immunoprecipitated from MCF10A, MCF10A-EphA2, or 
MCF10A-ΔC cells and incubated with phosphatase substrate, DiFMUP, following a 
time course (as described in Material & Methods). LMW-PTP phosphatase activity 
was elevated in MCF10A-EphA2 cells, compared to the levels in MCF10A-ΔC cells.  
(B) Average fold increase of LMW-PTP phophatase activity in different cell types 
after incubation with substrate for 2.5 hours.  (C) The association of LMW-PTP and 
EphA2 was assessed by GST-LMW-PTP pull-down assay. The levels of EphA2 that 
bound to GST-LMW-PTP were significantly higher in cells overexpressing EphA2 
than those expressing ΔC or vector control.  (D) MCF10A-EphA2 cells were 
transduced with control retrovirus pBABE (vector) or pBABE-LMW-PTP-C12S 
(C12S), a dominant negative mutant of LMW-PTP.  Tyrosine phosphorylation of 
p190 RhoGAP was decreased in cells expressing EphA2 and EphA2/vector cells.  
Expression of C12S restored phosphorylated tyrosine levels in MCF10A-EphA2 
cells, compared to parental or cells expressing ΔC.  (E-F) MCF10A-EphA2 cells were 
infected with retrovirus carrying either vector or the C12S mutant.  Stability of the 
adherens junctions in these cells was determined by calcium depletion.  C12S rescued 
cell-cell contact in MCF10A-EphA2 cells. 
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Src kinase interacts with EphA2 to alter adherens junction stability 
 In addition to LMW-PTP, Src kinase was shown to regulate p190 RhoGAP 
function (142-144).  Moreover, several EphA receptors were found to interact with 
Src family kinases (72, 145).  To determine if Src is involved in EphA2-mediated 
destabilization of the adherens junctions, total Src and tyrosine phosphorylated Src 
levels, as well as Src association with EphA2 receptor were assayed in cells 
overexpressing EphA2 or ΔC.  Src expression levels and tyrosine phosphorylation 
were not significantly changed in the cells overexpressing EphA2 or ΔC (data not 
shown).  In contrast, the levels of Src associated with the EphA2 receptor were 
significantly higher in MCF-10A-EphA2 cells than those in MCF-10A or MCF-10A-
ΔC cells (Fig. 16A and B).  Differential recruitment of Src kinase by EphA2 receptor 
in these cells suggests a possibility of Src kinase-dependent destabilization of cell-cell 
adhesion.  To investigate this possibility, MCF-10A cells overexpressing EphA2 were 
treated with the Src kinase inhibitor, PP2.  MCF-10A-EphA2 cells treated with 
vehicle control lost E-cadherin expression after calcium depletion for 8 hours (Fig. 
16C).  In contrast, treatment of cells with PP2 stabilized adherens junction (Fig. 16D), 
as determined by the increase E-cadherin levels at cell-cell contacts.   
 To test specifically whether association of EphA2 with Src is required for 
mediating the destabilization of the adherens junctions, we generated a series of 
tyrosine (Y) to phenylalanine (F) mutants in the juxtamembrane and kinase domains 
of EphA2 receptor.  These mutants, or control wild-type EphA2, were co-transfected 
with Src into COS7 cells, and the ability of Src to interact with these mutants was 
assessed by co-immunoprecipitation and western blot analysis.  While the majority of 
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EphA2 mutants were capable of interacting with Src, two kinase domain mutants, 
Y812F and Y816F, exhibited significantly decreased association with Src kinase (Fig. 
16E).  To determine the requirement of EphA2 interaction with Src in mediating the 
destabilization of the adherens junctions, Y812F, Y816F, or control wild-type EphA2 
were expressed in MCF-10A cells.  As before, overexpression of wild-type EphA2 
destabilized cell-cell adhesion (Fig. 16F).  However, EphA2 "uncoupling" mutants 
that are defective in binding Src, Y812F or Y816F, were unable to destabilize cell-
cell adhesion, as evident by strong E-cadherin staining at the cellular junction in 
calcium depletion assay (Fig. 16G&H). These results suggest that EphA2 recruitment 
of Src kinase is critical for destabilization of cell-cell adhesion. 
 To determine whether Src acts upstream or downstream of LMW-PTP in the 
EphA2 signaling cascade, MCF-10A/Y812F or MCF-10A/Y816F cells were 
transduced with retrovirus expressing LMW-PTP and assayed for E-cadherin 
localization at cell-cell contact in low calcium medium.  As shown in Figure 16I-L, 
expression of LMW-PTP in either MCF10-A/Y812F or MCF10-A/Y816F cells 
destabilizes adherens junction, suggesting that Src kinase functions upstream of 
LMW-PTP (see diagram in Figure 18). 
 
High levels of EphA2 expression correlate with accelerated destabilization of the 
adherens junction 
 
 EphA2 receptor tyrosine kinase overexpression is common in malignant tumor 
cells, and the level of EphA2 receptor expressed on tumor cells correlates with the 
degree of tumor malignancy (123).  To determine how the level of EphA2 expression 
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Figure 16.  EphA2 recruits Src kinase to regulate adherens junction stability.  
Association of EphA2 with Src kinase was measured by an MBP-EphA2 pull-down 
assay (A) and co-immunoprecipitation/western blot analysis (B).  (C-D)  Inhibition of 
Src activity restores adherens junction stability in MCF10A-EphA2 cells.  (E) Co-
immunoprecipitation of EphA2 and Src from COS7 cells transfected with Src and 
wild-type or mutant EphA2.  (F-G)   Overexpression of EphA2-Y812F and EphA2-
Y816F mutants in MCF10A cells fails to destabilize adherens junction, even after 8 
hrs of calcium depletion.  (I-L)  Overexpression of wild type LMW-PTP is sufficient 
to destabilize adherens junctions in MCF10A/ Y812F and MCF10A/ Y816F cells. 
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affects cell-cell adhesion, we first examined the EphA2 expression levels in MCF-
10A, MCF-10A/LZRS-EphA2, MCF-10A/Ad-EphA2, and two commonly used 
human breast cancer cell lines, BT-549 and MDA-MB-231.  As shown in Figure 17, 
EphA2 is expressed at low levels in MCF10A, a non-transformed breast epithelial 
cell line.  Expression of exogenous EphA2 receptor via LZRS retroviral transduction 
increased EphA2 expression modestly above endogenous level, but the EphA2 levels 
in theses cells are still considerably lower that those observed in two tumor cell lines 
or cells infected with adenoviruses (Fig. 17A).  Interestingly, although levels of 
EphA2 were significantly higher in MDA-MB-231 or BT-549 cells, the 
phosphorylation state of the receptor was dramatically lower in the tumor cells, 
possibly reflecting the fact that the tumor cells have lost cell-cell contact and were 
unable to interact with ephrin ligands on adjacent cells.   
 To determine the effect of EphA2 expression on cell-cell adhesion, we compared 
E-cadherin expression in low calcium medium among MCF-10A, MCF-10A/LZRS-
EphA2, or MCF-10A/Ad-EphA2.  Compared to MCF-10A or MCF-10A/LZRS-
EphA2, MCF-10A/Ade-EphA2 cells depleted of calcium exhibited a dramatic 
increase in rate at which the adherens junctions were disrupted (Fig. 17B).  Within 2 
hours of calcium depletion, overexpression of EphA2 in MCF-10A/Ade-EphA2 cells 
resulted in a complete loss of E-cadherin staining at cell-cell contacts.  In contrast, 
destabilization of the adherens junctions was only detected at 8 hours of calcium 
depletion in cells expressing moderate amounts of EphA2 (MCF-10A/LZRS-EphA2). 
Taken together, these data suggest that EphA2 overexpression can destabilize the  
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Figure 17.  Level of EphA2 overexpression determines rate of adherens junction 
disassembly.  (A) Expression and tyrosine phosphorylation of EphA2 receptor in 
various MCF10A cells and two breast cancer cell lines, BT-549, and MDA-MB-231, 
were determined by immunoprecipitation and western blot analysis.  (B-I)  MCF10A, 
MCF10A/LZRS-EphA2, MCF10A/LacZ, or MCF10A/Ad-EphA2 were 
immunostained for E-cadherin localization in the presence of normal or low calcium 
medium for 2 hours. 
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adherens junctions and the rate of destabilization of the adherens junctions is 
dependent upon EphA2 levels. 
 
Discussion 
 Despite significant evidence supporting a role for EphA2 receptor tyrosine kinase 
in tumorigenesis, the mechanisms by which EphA2 overexpression contributes to 
tumor progression are not completely understood.  Adherens junctions play a 
fundamental role in embryonic development and the in the maintenance of tissue 
architecture in adults.  Loss of cadherin function has been associated with migratory 
behavior in vitro and is a hallmark of invasive carcinoma in vivo.  Previous studies 
showed that loss of E-cadherin inhibits the expression of Eph receptors in embryonic 
stem cells (63), suggesting EphA2 expression is regulated by E-cadherin.  However, 
many malignant tumor cells that have lost E-cadherin expression exhibited elevated 
EphA2 receptor levels (40, 92), raising the question of whether EphA2 levels affect 
the adherens junctions.  In this report, we studied how cell-cell adhesion is affected 
by EphA2 overexpression.  We found that overexpression of EphA2 does not induce 
epithelial to mesenchymal transition directly; however, elevated EphA2 expression 
destabilizes adherens junctions and accelerates dissociation of cell-cell contact.  The 
rate of destabilization of the adherens junctions is dependent upon EphA2 levels; 
higher EphA2 expression leads to more rapid down-regulation of E-cadherin 
localization at cell-cell contacts.  The fact that overexpression of EphA2 also affects 
E-cadherin suggests that a reciprocal regulation exists between E-cadherin and 
EphA2.  A delicate balance of relative levels of E-cadherin and EphA2 receptor
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Figure 18.  A model for how EphA2 overexpression promotes destabilization of 
adherens junctions.  Overexpression of EphA2 increases the recruitment of LMW-
PTP and Src kinase.  Increased LMW-PTP phosphatase activity dephosphorylates 
p190 RhoGAP and inhibits p190 RhoGAP activity.  Decreased p190 RhoGAP 
activity in turn upregulates activated Rho-GTP levels.  Rho signaling through ROCK 
destabilizes the adherens junction. 
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appears to ensure normal cellular architecture and function. 
 Several cellular mechanisms have been proposed to perturb adherens junctions.  
These include cleavage of the cadherin extracellular domain, phosphorylation of the 
cadherin complexes, increased turnover of cadherin receptors, and regulation of 
cytoskeletal attachment to cadherin complexes (120, 126, 146).  Activation of 
receptor tyrosine kinases (RTKs) has been shown to destabilize adherens junctions 
through phosphorylation of cadherin/catenin junctional proteins (146) and ephrin-A1 
stimulation is reported to induce β-catenin phosphorylation in HT-29 colon 
carcinoma cells (64).  However, we did not observe changes in tyrosine 
phosphorylation of E-cadherin, p120, and α− or β-catenin among MCF-10A, MCF-
10A/EphA2, or MCF-10A/ΔC cells, a result that is consistent with the data reported 
by Orsulic et al (63) and by Kinch et al (personal communication).  Nor did we detect 
any alternations of cadherin expression or composition of adherens junction complex 
(Fig 11).  In addition, no significant changes in cortical actin cytoskeleton were 
observed, suggesting that the effects of EphA2 on adhesive strength are probably not 
due to gross disruption of the cytoskeleton. 
 A growing number of studies have linked Rho family small GTPases with 
cadherin-dependent cell-cell contacts [reviewed in (120, 124, 126)].  Rho family 
GTPases can regulate cell-cell adhesion by acting on the cadherin-catenin complex or 
on the actin cytoskeleton and other components.  Rac1 and Cdc42 have been shown 
to directly affect the cadherin-catenin complex by modulating the interaction of 
IQGAP1, a GTPase activating protein, with β-catenin (147).  In contrast, activation of 
RhoA has been implicated in regulating E-cadherin-mediated adhesive activity 
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through the actin cytoskeleton (126, 148).  Here we show that EphA2 signaling 
activates RhoA GTPase.  As the ROCK kinase inhibitor suppresses EphA2-induced 
destabilization of cell-cell adhesion, these data suggest a critical role of EphA2-
induced RhoA activation in regulating the strength of adherens junctions.   In 
fibroblasts, Rho activity can be regulated by Rac via a signaling pathway involving 
ROS, LMW-PTP, and p190 RhoGAP (130).  More recently, Wildenberg et al showed 
that a p120 catenin-p190 RhoGAP interaction is required for Rac inhibition of Rho in 
the stabilization of adherens junctions (135).  Although EphA2 receptor activation in 
vascular endothelial cells upregulates Rac1 activity (25), EphA2 receptor 
overexpression in mammary epithelial cells does not appear to affect Rac-GTP levels 
(Fig 13A).  Enhanced RhoA activity in MCF-10A-EphA2 cells is apparently 
regulated by enhanced LMW-PTP phosphatase activity and inhibition of tyrosine 
phosphorylation of p190 RhoGAP, ultimately leading to the destabilization of cell-
cell adhesion (diagramed in Fig 18).     
 It is interesting to note that while LMW-PTP can be activated by EphA receptors 
[this report and (129)], EphA2 receptor has also been shown to be a substrate for the 
same phosphatase (68, 71).  However, in our system, phosphorylation of EphA2 does 
not appear to be affected by LMW-PTP activity.  While a general PTP inhibitor, 
pervanadate, increased EphA2 phosphorylation, overexpression of wild-type or a 
C12S mutant of LMW-PTP did not change the EphA2 phosphorylation level 
significantly (data not shown), suggesting that EphA2 may not be a major substrate of 
LMW-PTP in MCF10A cells. 
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 How does EphA receptor activation enhance LMW-PTP activity?  In the case of 
EphA8, the kinase activity of the receptor directly phosphorylates LMW-PTP (129).  
However, direct phosphorylation of LMW-PTP by EphA2 was not observed in these 
cells, indicating that EphA2 regulates LMW-PTP activity by alternative 
mechanism(s).  One possible mechanism is through Src kinase.  Although Src can 
phosphorylate both LMW-PTP and p190 RhoGAP (142-144, 149), the phenotype of 
MCF-10A-EphA2 cells suggest that p190 RhoGAP is most likely not a candidate 
substrate for Src.  As EphA2 can physically associate with both Src kinase and 
LMW-PTP, Src could possibly regulate cell-cell adhesion through modulating LMW-
PTP activity.  Alternatively, Src could also affect adherens junctions by upregulating 
Rho GEF activity.  Further experiments are needed to dissect these possibilities. 
 In addition to adherens junctions, tight junctions also contribute to intercellular 
junctional complexes (124). Members of Eph family have also been implicated in 
regulating tight junctions.  Ephrin-B1 binds to Claudin-1 and Claudin-4, which are 
components of tight junction complexes. In addition, ephrin-B1 is phosphorylated in 
a Src kinase-dependent manner upon cell-cell contact (150).  Furthermore, Tanaka et 
al reported that EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates 
paracellular permeability in MDCK cells (65).  Whether EphA2 overexpression in 
MCF-10A cells also affects tight junctions in addition to regulation of adherens 
junctions still remains to be determined.  Furthermore, it will be interesting to 
determine whether other members of Eph RTK family also play a role in regulating 
adherens junctions. 
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 In summary, our results support a role of EphA2 receptor in regulation of cell-cell 
adhesion.  EphA2 overexpression likely promotes destabilization of adherens junction 
through a signaling pathway of recruitment of Src kinase, enhanced LMW-PTP 
activity, inhibition of p190 RhoGAP, and activation of RhoA GTPase.  As EphA2 
level is linked to tumor malignancy, these studies provide a foundation for 
investigating EphA2 as a potential target for therapeutic intervention. 
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CHAPTER V 
 
IDENTIFICATION AND FUNCTIONAL ANALYSIS OF 
PHOSPHORYLATED TYROSINE RESIDUES WITHIN EPHA2 RECEPTOR 
TYROSINE KINASE 
 
Introduction 
 
 The Eph receptors belong to a large family of receptor tyrosine kinases (RTKs) 
that regulate a variety of physiological processes during development and contribute 
to the pathogenesis of diseases such as cancer (3, 81).  One of the key events 
important both in embryogenesis and pathogenesis in adult organisms is 
angiogenesis, the process by which new blood vessels are formed from pre-existing 
vasculature.  On the basis of sequence homology and binding affinity, the Eph 
receptors are divided into two subclasses.  EphA receptors bind preferentially to the 
glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands, while EphB receptors 
bind preferentially to the transmembrane ephrin-B ligands (87).  Both class A and 
class B Eph receptors have been implicated in regulation of vascular remodeling and 
angiogenesis.  Targeted disruption of several class B RTKs and ephrin-B ligands 
resulted in defects in angiogenic remodeling of the rudimentary embryonic 
vasculature (12, 13, 16, 151).  Manipulation of the level of one receptor, EphB4, in 
tumor cells also affected tumor angiogenesis in adult animals (114, 152).  In the A 
class, ephrin-A1 stimulates endothelial cell migration and assembly in culture (17, 
22) and induces corneal angiogenesis in vivo (21, 153).  More recently, Eph receptors 
have been detected in tumor blood vessel endothelial cells (13, 81).  Inhibition of 
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class A Eph receptor signaling by soluble EphA2-Fc or EphA3-Fc receptors 
decreased tumor volume, tumor angiogenesis, and metastatic progression in vivo (23, 
39, 97).  A main target of soluble EphA receptors appears to be EphA2, as EphA2-
deficient endothelial cells fail to migrate and assemble in vitro (25) and loss of 
EphA2 receptor resulted in impaired tumor growth and metastasis in vivo (24).  
 The binding of ephrin ligands to Eph receptors induces the transphosphorylation 
of the cytoplasmic domains and initiates kinase activity.  Extensive tyrosine 
phosphorylation of the activated Eph receptor is not only induced by auto/trans-
phosphorylation, but also elicited by receptor associated protein tyrosine kinases such 
as Src family kinases (3).  Many phosphorylated tyrosine residues in the EphB 
receptors and ephrin-B ligands in neuronal cells/tissues have been mapped by both 
phosphopeptide mapping using two-dimensional chromatography, and by MALDI 
mass spectrometry (154-156).  Several tyrosine-phosphorylation sites in EphA3 and 
EphA4 have also been identified by mutational analysis on sites homologous to those 
in EphB receptors (59, 156).  However, as these phosphorylated tyrosine residues are 
not mapped in endothelial cells, their role in signal transduction leading to angiogenic 
responses is not clear.  Moreover, phosphorylated tyrosine residues have not been 
mapped in EphA2, a major EphA receptor that is critical in mediating tumor 
angiogenesis. 
 We have previously shown that activation of EphA2 receptor in endothelial cells 
recruits Vav GEFs, resulting in upregulation of GTP-bound activated Rac1 GTPase 
and endothelial cell migration (56).  The Vav GEF/Rac1 pathway appears to be 
regulated by PI3 kinase, as PI3 kinase-specific inhibitors wortmanin and LY294002, 
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or a dominant negative p85 subunit of PI3 kinase, block ephrin-A1-induced Rac1 
activation and endothelial cell migration (25).  As the SH2 domains of both Vav 
GEFs and p85 subunit of the PI3 kinase are capable of binding to phosphorylated 
EphA2 receptor (56, 69), we sought to identify critical phosphorylated tyrosine 
residues that mediate the recruitment of Vav GEFs and p85.  As a first step, we have 
used a combination of mass spectrometry analysis and traditional phosphopeptide 
mapping to identify the phosphorylated tyrosine residues within the EphA2 receptor.  
Four phosphorylated tyrosine residues in the cytoplasmic domain of the EphA2 
receptor were identified.  Changing three of these sites to phenylalanine or glutamic 
acid resulted in an EphA2 mutant that could not be phosphorylated, failed to interact 
with p85 or Vav GEFs, and was unable to rescue defects in endothelial assembly in 
EphA2-deficient cells in vitro and in vivo.  Our results suggest that phosphorylation 
of tyrosine Y587/593 and Y734 is critical in recruitment of Vav and p85, 
respectively.  Phosphorylation of these tyrosines is also essential in activation of Rac1 
GTPase and promoting angiogenic responses and tumor neovascularization. 
 
Results 
Mapping tyrosine phosphorylation sites in EphA2 receptor 
 To identify the phosphorylated tyrosine residues in the cytoplasmic domain of 
EphA2 receptor induced upon binding to ephrin-A1 ligand, we initially expressed 
EphA2 in COS7 cells.  Immunoprecipitated EphA2 proteins were digested with 
trypsin and subjected to LC-MS mass spectrometric analysis.  Greater than 50% of 
the tryptic peptides were not detected and were therefore not analyzed.  Among the 
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Table 2.  Tryptic peptides from in vivo phosphorylated EphA2 identified by Mass 
Spectrometry 
 
Tyrosine Masscalc Massmeasured Δ   Peptide 
 
Y593  2068.9  2071.1  2.2         TYVDPHTYPO4EDPNQAVLK 
Y734  1375.6  1375.4  0.2  YLANMOXNYPO4VHR 
Y771  1761.7  1762.3  0.6  VLEDDPEATYPO4TTSGGK 
 
Masscalc, calculated mass. Massmeasured, measured mass.  Δ, difference between measured 
mass and calculated mass.  OX, oxidized methionine  
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remaining tryptic peptides analyzed, three phosphorylated peptides were identified 
which contained Y593 in the juxtamembrane domain, as well as Y734 and Y771 in 
the kinase domain (Figure 19 and Table 2). 
 To verify phosphorylation sites mapped by mass spectrometry and to identify 
additional sites not covered by mass spectrometric analysis, we performed 
phosphopeptide mapping by two-dimensional chromatography in conjunction with 
site-directed mutagenesis.  We chose to use immortalized EphA2-null and wild-type 
control endothelial cell lines for our analysis, as the EphA2-null background 
facilitates mutational analysis and subsequent functional assays.  These endothelial 
cells were isolated from EphA2-deficient mice that were bred into the H-2Kb-tsA58 
transgenic "Immorto-mouse" background (157).  These immorto-mice harbor a 
temperature sensitive SV40 T antigen (TAg) cassette driven by the mouse major 
histocompatibility complex H-2Kb promoter, which permits expression in a wide 
array of tissues.  In addition, the promoter is responsive to interferon-γ, permitting 
elevated expression of the TAg in cells derived from these mice when cultured at 
33ºC in the presence of interferon-γ.  Once cells are placed at physiologic temperature 
(37ºC), protein levels of the thermolabile TAg are downregulated and cells are 
restored to a non-transformed state over the course of several days (157).  
 Wild-type and a panel of Y to F mutant EphA2 constructs were stably expressed 
in endothelial cells via retroviral transduction using the LZRS retroviral system (127).   
In vitro kinase assays using an exogenous substrate revealed that Y593E, 
Y587/593EE, Y734F and Y771F mutations do no affect kinase activity significantly.  
However, Y587F and Y929F inhibited, and Y593F abolished EphA2 kinase activity 
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Figure 19.  In vivo tyrosine phosphorylation sites of EphA2 in transfected COS7 cells. (A-C) 
LC-MS mass spectra of tyrosine-phosphorylated tryptic peptides from immunoprecipitated 
EphA2.  Tyrosine-phosphorylated peptides were isolated from the resulting peptide mixture 
and purified by reverse phase chromatography.  Peaks corresponding to tyrosine-
phosphorylated peptides of EphA2 are denoted by their masses and sequences. (A) Triply 
charged peptide with m/z 691.4. (B) Doubly charged peptide with m/z 688.69. (C) Doubly 
charged peptide with m/z 882.14.  (D) Schematic diagram of phosphorylated tyrosine 
residues in the cytoplasmic domains of the EphA2 receptor. 
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(Figure 20A).  Y587/593 and Y771 appeared to be major tyrosine phosphorylation 
sites in the EphA2 receptor, as phosphorylation of EphA2 was markedly reduced in 
Y587/593EE and Y771F mutants (Figure 20B), despite the observation that these 
mutants retained kinase activity. 
 Phosphopeptide mapping by two dimensional chromatography detected five 
distinct phosphopeptides in activated wild-type EphA2 (Figure 21, Experiment #1).  
To identify the phosphorylated tyrosines within the tryptic peptides, the 
phosphorylated tyrosines identified by mass spectrometry analysis or those tyrosine 
residues that were not covered were mutated to phenylalanine.  These include 
tyrosine residues in the juxtamembrane region (Y587F, Y593F), kinase domain 
(Y685F, Y693F, Y734F, Y771F, Y802F, Y812F, Y816F, Y846F), and the carboxy 
terminal SAM domain (Y921F, Y929F, Y959F).  Because the Y593F could not be 
analyzed due to defective kinase activity resulting in insufficient γ-32P incorporation, 
a tyrosine to glutamic acid mutant, Y593E, that retained kinase activity was used for 
further analysis.  Tryptic phosphopeptide maps of wild-type microvascular 
endothelial cells were similar to those EphA2-null cells reconstituted with wild-type 
EphA2 receptor (Figure 21, Experiment #1).  Each of the EphA2 mutants was 
deficient in certain γ-32P-labeled phosphopeptides.  The Y587F mutant lacks two 
major phosphopeptides (a & b). Phosphopeptide c was absent in the Y593E mutant, 
and phosphopeptide d was absent in the Y771F mutant. Phosphorylation of Y734 was 
identified in a separate experiment when the first dimension chromatography was 
performed in the reverse direction (Figure 21, Experiment #2).  Taken together, these 
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Figure 20.  Wild type and mutant EphA2 kinase activity.  (A) In vitro kinase assay was 
performed on EphA2 immunoprecipitated from EphA2-null endothelial cells reconstituted 
with wild-type or mutant EphA2 via LZRS retroviral transduction.  EphA2 kinase activity 
was measured by its ability to phosphorylate the synthetic substrate, poly (glu:tyr) (4:1).  (B) 
Phosphorylated EphA2 levels were assayed in EphA2-null endothelial cells reconstituted 
with wild type or mutant EphA2.  EphA2 was immunoprecipitated by an anti-EphA2 
antibody, and tyrosine phosphorylation was detected by a mixture of anti-pY20 and anti-
pY99 antibodies.  
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results suggest that Y587, Y593, Y771, and Y734 are likely to be autophosphorylated 
in vascular endothelial cells.  
 
Vav GEFs binds to pY587/Y593 in the juxtamembrane region and p85 interacts 
to pY734 in the EphA2 kinase domain 
 
 We have previously shown that guanine nucleotide exchange factors Vav2 and 
Vav3 are recruited to phosphorylated EphA2 receptor, and the binding is significantly 
reduced in Y587F/Y593F double mutants (56).  To assess which phosphorylated 
tyrosine residue, or whether both pY sites, in the juxtamembrane region of the EphA2 
is/are required for interaction with Vav proteins, we performed a series of co-
immunoprecipitation experiments coupled with western blot analysis.  As shown in 
Figure 22A, mutation at either Y587 or Y593 inhibited binding of EphA2 receptor to 
Vav2 and Vav3 exchange factors, suggesting that both sites are required for optimal 
binding to Vav GEFs.  Interestingly, Y929 in the SAM domain also appears to affect 
binding to Vav3, but not Vav2 GEF.  As phosphorylation of Y929 was not detected 
by in vitro kinase assay, this site might be phosphorylated by another tyrosine kinase 
in vivo. 
 In addition to binding to Vav GEFs, we and others have shown that activated 
EphA2 receptor also recruits the p85 subunit of the PI3 kinase, and PI3 kinase 
activity is required for ephrin-A1 induced Rac1 GTPase activation and endothelial 
cell migration (25, 69).  However, although the SH2 domain of the p85 was shown to 
interact with the kinase domain of the EphA2 receptor (69), the precise 
phosphotyrosine residue that mediates this interaction is unknown.    Thus, a panel of 
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Figure 21.  Tryptic phosphopeptide maps of wild-type and mutant forms of EphA2. Wild-
type and mutant forms of EphA2 were expressed in EphA2-null endothelial cells via LZRS 
retroviral transduction.  EphA2 receptors were immunoprecipitated, phosphorylated in the 
presence of [γ-32P] ATP, and resolved by SDS-PAGE.  Radioactive bands representing 
phosphorylated forms of EphA2 were excised, digested with trypsin, and subjected to two-
dimensional chromatography. Four peptides were detected (labeled a-d) in both wild-type and 
EphA2-null reconstituted with wild-type EphA2 in Experiment #1.  An additional 
phosphopeptide (labeled e) was identified in Experimental #2 when the first dimension 
chromatography was performed in the reverse direction.  Peptides containing identified 
phosphorylated tyrosines are indicated on the left in two schematic representations, one for 
each set of experiments. 
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EphA2 mutants containing Y to F mutations was tested for the ability to bind to p85.  
As shown in Figure 22B, while p85 binds to Y587F, Y593E, Y587/593EE, and 
Y771F as well as wild-type EphA2, it fails to bind to Y734F and Y929F, suggesting 
that p85 interacts with phosphorylated Y734 in the kinase domain and Y929 in the 
SAM domain. 
 We have previously shown that the SH2 domain of Vav3 binds to EphA2 in a 
yeast two-hybrid system and in an in vitro binding assay (56).  To determine the 
mechanism of interaction between EphA2 and Vav/p85 in mammalian cells, we 
performed co-immunoprecipitation assays using the SH2 domain of p85 or Vav3, or a 
Vav2ΔSH2 mutant.  As shown in Figure 22C, the SH2 domain of p85 or Vav3 were 
capable of binding to EphA2 receptor, whereas the Vav2ΔSH2 mutant fails to interact 
with EphA2, suggesting that interaction between EphA2 and Vav/p85 is mediated by 
binding between SH2 domains and pY sites in EphA2.  Taken together, our data 
suggest that VavGEFs and p85 are major (but perhaps not the sole) binding partners 
of EphA2 receptor. 
 
Mutations that uncouple EphA2 receptor with Vav or p85 inhibit ephrin-A1-
induced Rac1 GTPase activation and migration 
 
 Dynamic regulation of the actin cytoskeleton is critical in cell migration, and Rho 
family GTPases are known to be key regulators of this process and have been shown 
to be necessary for endothelial cell migration (103).   We have previously reported 
that ephrin-A1 stimulation of endothelial cells induces activation of Rac1 GTPase 
through activation of guanine nucleotide exchange factors Vav2/Vav3 (56).  In 
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Figure 22.  Mapping of Vav and p85 binding sites in EphA2 receptor.   (A) The wild-type or 
mutant EphA2 and Vav2 or Vav3 were co-expressed in the COS 7 cells.  The Vav2 or Vav3 
proteins were immunoprecipitated and western blotted using antibodies against EphA2.  The 
blots were stripped and reprobed using antibodies against Vav2 or Vav3 for confirmation of 
equal loading (for Vav2 and Vav3 p<0.01).  (B) The wild-type or mutant EphA2 and Flag-
tagged p85 were co-expressed in the COS 7 cells.  The p85 proteins were immunoprecipitated 
and western blotted using antibodies against EphA2. The blots were stripped and reprobed by 
anti-Flag for equal loading.  EE, a double Y to E mutation (Y587E/Y593E) in the 
juxtamembrane domain (p<0.01). (C) Wild-type or mutant Vav2, Vav3, or p85 were co-
expressed with EphA2 in COS7 cells. EphA2 or Vav proteins were immunoprecipitated by 
appropriate antibodies, and western blotted by antibodies against p85 and EphA2, respectively. 
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addition, ephrin-A1 induced Rac1 activation is dependent on the activity of PI3 
kinase (25).   As Y587/593 and Y734 are required for recruitment of Vav GEFs and 
p85, respectively (Figure 22), we tested whether Y587/593EE and Y734F could 
affect ephrin-A1-induced Rac1 activation in endothelial cells.  Cells were stimulated 
with ephrin-A1 and activated GTP-bound Rac1 or Cdc42 was isolated from lysates by 
precipitation with Pak1 p21-binding domain (PBD)-GST fusion proteins.  As shown 
in Figure 23A, consistent with our previous findings (25), ephrin-A1 induced Rac1  
activation in EphA2-null endothelial cells reconstituted with wild-type EphA2, but 
not in control LZRS infected cells.  In contrast, Y587/593EE, Y734F, and Y929F 
mutants fail to restore Rac1-GTP level, suggesting that recruitment of p85 and Vav 
proteins to EphA2 receptor is critical for ephrin-A1-induced Rac1 activation.  
Activated Cdc42 was not significantly changed in response to ephrin-A1 stimulation 
in either wild-type or EphA2 mutants (Figure 23B), indicating that EphA2 is not 
directly involved in regulating Cdc42 activity. 
 As activation of Rac1 is critical for ephrin-A1-induced endothelial cell migration 
(25), we tested whether cell migration is impaired in EphA2-null endothelial cells 
reconstituted with uncoupling EphA2 mutants.  As shown in Figure 23C, EphA2-null 
endothelial cells exhibit a defect in ephrin-A1-induced cell migration.  Re-expression 
of wild-type EphA2 receptor rescued migration defects in EphA2 knock out 
endothelial cells.  In contrast, expression of Y587/593EE or Y734F mutants fail to 
promote ephrin-A1-induced cell migration, suggesting that phosphorylation of 
Y587/Y593 and Y734 is critical for recruitment of p85 subunit of PI3 kinase and Vav  
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Figure 23.  Phosphorylation of Y587/593 and Y734 in the EphA2 receptor is required for 
EphA2-dependent Rac1 activation and cell migration. Active GTP-bound forms of Rac1 (A) 
and Cdc42 (B) were analyzed by Pak-PBD pull-down followed by immunoblot in lysates from 
EphA2-null endothelial cells reconstituted with wild-type or mutant EphA2 in response to 
ephrin-A1 stimulation.  Total Rac1 and Cdc42 levels within the lysates prior to PBD-pulldown 
were detected by immunoblot.  Data are a representation of 4 independent experiments.  (C) 
EphA2-null endothelial cells reconstituted Y587/593EE or Y734F mutant displayed significant 
reduced migration in response to ephrin-A1 stimulation in transwell migration assays (p<0.01, 
EphA2 versus Y587/593EE or Y734, two-tailed paired student t test). 
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GEFs, which transduce downstream signaling to activate Rac1 GTPase and cell 
migration. 
 
Functions of EphA2 phosphorylated tyrosine residues in vascular assembly and 
tumor angiogenesis 
 
 Angiogenesis is a complex, multi-stage process by which new blood vessels are 
formed from pre-existing vasculature.  Two critical steps in this process are 
endothelial cell migration and assembly into new tubules.  To test the functional roles 
of phosphorylated tyrosine residues of EphA2 receptor in ephrin-A1-induced 
angiogenic responses, we measured the vascular assembly in EphA2-null endothelial 
cells reconstituted with EphA2 mutants.  Ephrin-A1 stimulation induced wild-type, 
but not EphA2-deficient, endothelial cell assembly into an interconnected vascular 
network on a thin layer of Matrigel.  Re-expression of wild-type EphA2, but not 
empty control vector, by LZRS retrovirus-mediated infection rescued defects in 
EphA2-null endothelial cells.  Likewise, expression of mutant Y593E or Y771F in 
EphA2-null cells restored the ability of cells to assemble and form interconnecting 
cellular network on Matrigel.  In contrast, EphA2 mutations in the juxtamembrane 
(Y587F, Y587/Y593EE), kinase domain (Y734F), or SAM domain (Y929F) inhibited 
ephrin-A1-induced vascular assembly (Figure 24). 
 To test whether phosphorylated tyrosines important in mediating vascular 
assembly in vitro are also critical in tumor angiogenesis in vivo, we performed tumor 
cell/endothelial cell co-transplantation experiments using EphA2-null endothelial cell 
reconstituted with wild-type or mutant EphA2 receptors.  For co-transplantation, 
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Figure 24. Phosphorylation of Y587/593, Y734, and Y929 in the EphA2 receptor is required for 
vascular assembly in vitro. (A) EphA2-null endothelial cells reconstituted with wild-type or 
mutant EphA2 were plated on a thin layer of growth-factor reduced Matrigel in the presence of 
ephrin-A1 to examine and quantify vascular assembly.  After 9 hours, the endothelial cells were 
photographed.  (B) Average branch length was scored using morphometric software analysis.  
Four fields per culture were scored for each condition and data are means +/- S.D. of 3 
independent experiments  (p<0.05, EphA2 versus Y587F, Y593F, Y587/593EE, Y734F or 
Y929F, two-tailed paired student t test). 
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endothelial cells were infected with adenoviruses encoding nuclear β-galactosidase 
(Ad-βgal) in order to distinguish them from endogenous host endothelium.  These 
labeled endothelial cells were then co-transplanted with 4T1 mammary carcinoma 
cells in Matrigel into the subcutaneous dorsal flank of nude female mice. After 7 
days, tumor-endothelial cell Matrigel plugs were harvested, sectioned, and double 
stained with X-gal and CD31 to identify donor endothelial cells.  As shown in Figure 
25, significant numbers of LacZ positive donor endothelial cells reconstituted with 
either wild-type or Y921F control EphA2 mutant have incorporated into tumor (panel 
A) or peripheral vessels (panel B).  In contrast, EphA2-deficient donor endothelial 
cells, as well as cells reconstituted with Y587/Y593EE, Y734F, or Y929F, remained 
isolated and failed to incorporate into tumor vasculature.  In addition, tumor volume 
was significantly increased in tumors harboring donor endothelial cell reconstituted 
with wild-type or Y921F control EphA2, relative to tumors containing EphA2-
deficient endothelial cells, or cells reconstitute with Y587/593EE, Y734F, or Y929F 
(Figure 25C).  Taken together, these data suggest that phosphorylated tyrosine 
residues, Y587/593, Y734, and Y929, are critical in EphA2 signal transduction and 
tumor angiogenesis in vivo. 
 
Discussion 
 A wealth of evidence demonstrated that ephrin-A ligand stimulation of EphA2 
receptors activates a signaling cascade that modulates actin cytoskeleton dynamics 
and regulates cell-cell and cell-matrix adhesion and cell motility (25, 56, 128).   
Phosphorylated tyrosine residues on the EphA2 receptor were thought to play a
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Figure 25. Phosphorylation of Y587/593, Y734, and Y929 in the EphA2 receptor is required 
for efficient incorporation of endothelial cells into tumor vasculature in vivo.   4T1 tumor 
cells were mixed with Ad-LacZ transduced EphA2-null endothelial cells reconstituted with 
wild-type or mutant EphA2 in Matrigel and co-transplanted subcutaneously into Balb/c nude 
female mice.  Tumors were collected 7 days post-transplantation. (A and B) Tumor sections 
were co-stained with X-gal (blue) and anti-CD31 antibodies (brown in panel B) to visualize 
donor endothelium and counterstained with eosin to visualize tumor cells (pink).  Donor 
endothelial cells derived from EphA2-null reconstituted with wild-type EphA2 or control 
Y921F mutant coalesced around tumor cell clusters and displayed an elongated phenotype 
typical of endothelial cells.  In contrast, endothelial cells derived from EphA2-null cells 
expressing Y734F mutant or control vector LZRS remained isolated and failed to incorporate 
into tumor vessels.  Arrowheads indicate exogenous endothelial cells, and * indicates central 
lumen of chimeric vessels in panel B.  (C) Tumor volume was significantly decreased for 
tumors harboring EphA2-null endothelial cells expressing Y587/593EE, Y734F, or Y929 
mutant or control LZRS vector, relative to tumors co-transplanted with those expressing wild-
type EphA2 or control Y921F mutant (p<0.05, EphA2 versus Y587/593EE, Y734F or 
Y929F, two-tailed paired student t test).  Data are representative of three independent 
experiments.   (D) Quantitation of LacZ positive cells from tumor sections (p<0.001). 
D. 
*
* * * *
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critical role in the recruitment of SH2- or PTB-domain containing signaling 
molecules such as the p85 subunit of PI3 kinase (69), adaptor proteins SLAP (70) and 
Shc (60), tyrosine phosphatase SHP-2 (67) and LMW-PTP (68, 141), ubiquitin ligase 
c-Cbl (66, 158), and guanine nucleotide exchange factors Vav2 and Vav3 (56).  In the 
endothelial cells, we have previously shown that either PI3 kinase inhibitors or a 
dominant negative p85 mutant significantly inhibited ephrin-A1 ligand-induced 
endothelial cell migration (25).  Likewise, Vav2/3-deficient endothelial cells were 
incapable of mediating cell migration and assembly upon ephrin-A1 stimulation (56).  
These data indicate important roles of PI3 kinase and Vav GEFs in ephrin-A-elicited 
angiogenic responses.  However, as these signaling molecules also act downstream of 
many receptor tyrosine kinases, it remains unclear whether recruitment of these 
proteins by EphA2 receptor is critical for endothelial cell function.  As a first step to 
dissect the specific function of different phosphorylated tyrosine residues in the 
activated EphA2 receptor, we undertook mapping major tyrosine-phosphorylation 
sites on the EphA2 receptor.  We found that 4 of the 15 tyrosines (Y587, Y593, Y734, 
and Y771) in the EphA2 cytoplasmic domain were phosphorylated in vascular 
endothelial cells.   
 Two tyrosine residues in the juxtamembrane region of the EphB receptor were 
previously shown to be phosphorylated in vivo and are important in regulating kinase 
activity (10, 156).  Of the corresponding two juxtamembrane tyrosine residues in the 
EphA2 receptor, we found that both Y587 and Y593 were phosphorylated in our in 
vitro kinase assay.  However, only the phosphorylation of Y593 was detected in vivo 
in COS7 cells by LC-MS mass spectrometric analysis.  This apparent discrepancy is 
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most likely due to dephosphorylation of Y587 in vivo upon ephrin-A1 stimulation for 
15 minutes.  As predicted, Y587 plays a critical role in endothelial cell assembly in 
vitro and in endothelial cell incorporation into tumor vasculature in vivo (Figures 24 
& 25).  Y593 was phosphorylated in COS7 cells and in vascular endothelial cells 
(Figures 19-21).  Consistent with data shown in EphB receptor (10, 156), the Y593F 
mutation abolished kinase activity.  Although the Y593E mutation inhibited binding 
of EphA2 to Vav GEFs (Fig. 22), it is somewhat surprising that it did not affect 
ephrin-A1-induced vascular assembly (Fig. 24).  It is conceivable that residual levels 
of EphA2 binding to Vav GEFs through Y587 in vascular endothelial cells may be 
sufficient to transduce signals and regulate angiogenic responses. 
 For tyrosine residues in the kinase domain, Y771 resides in the activation loop of 
the kinase and was phosphorylated in both the in vitro kinase assay and in vivo as 
shown by mass spectrometric analysis (Figures 19-21).  Interestingly, the Y771F 
mutant retains kinase activity and no obvious phenotype was detected in our assays.  
Mass spectrometric analysis and two dimensional phosphopeptide mapping also 
revealed a novel phosphorylated tyrosine residue, Y734.  The significance of Y734 
phosphorylation appears to recruit the p85 subunit of PI3 kinase (Figure 22), as the 
Y734F mutant failed to rescue cell migration and vascular assembly in EphA2-
deficient endothelial cells.  
 Of the three tyrosines in the SAM domain, Y921, Y929, Y959, none of them was 
identified to be phosphorylated by either mass spectrometry or phosphopeptide 
mapping analysis.  Yet, Y929F inhibited ephrin-A1 induced vascular assembly and 
endothelial cell incorporation into tumor vasculature in vivo (Figures 24 & 25).  As 
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Y929F also displays reduced kinase activity, the phenotype could be attributed to 
either lack of phosphorylation at the Y929 site or insufficient kinase activity, or a 
combination of both deficiencies. It is also possible that Y929 was not 
phosphorylated within 15 minutes of stimulation by ephrin-A1, but was 
phosphorylated in a different time frame.  Alternatively, Y929 may not be 
phosphorylated in COS7 cells, but may be phosphorylated in endothelial cells in vivo 
by protein tyrosine kinases other than EphA2.  Our binding data suggest that Vav3 
and p85 interact with pY929 (Fig. 22).  In addition, Stein et al., reported that LMW-
PTP and Grb10 can bind to corresponding site in EphB1 receptor (137, 159).  If 
LMW-PTP also interacts with pY929 in EphA2 receptor, it may attenuate its 
signaling by dephosphorylation of EphA2 receptor, as demonstrated in tumor cells 
(68, 141).  Alternatively, LMW-PTP may transduce EphA2 signaling by interacting 
with p190RhoGAP to regulate the activity of Rho GTPases (Fang et al., 2008, in 
press).  It remains to be determined whether LMW-PTP can interact with EphA2 and 
modulate ephrin-A1-induced angiogenic responses. 
 Our results revealed that phosphorylated tyrosine residues in the EphA2 receptor 
are not only critical for signal transduction in cultured microvascular endothelial cells 
in vitro, but also important for these cells to participate in tumor angiogenesis in vivo.  
It is interesting to note that tumors grow better in the presence of wild-type donor 
endothelial cells than EphA2-null cells or null cells reconstituted with Y587/593EE, 
Y734F, or Y929F mutants.  This may not be entirely due to extra oxygen and 
nutrients supplied by new blood vessels, as tumor blood flow appeared to be 
restricted to peripheral vessels distant from the tumor mass.  It is possible that there 
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could be paracrine signaling from donor endothelial cells to tumor cells to promote 
tumor growth, and this signal(s) is absent or diminished in EphA2-null endothelial 
cells.  Indeed, we have previously shown that ephrin-A1 regulates soluble growth 
factor production in tumor cells (160).  The growth factors/signaling molecules that 
are modulated by EphA2 receptor activation in vascular endothelial cells remain to be 
determined. 
 In summary, mapping of phosphorylated tyrosine residues in the EphA2 receptor 
allowed us to generate tyrosine to phenylalanine mutants that were used to identify 
binding sites to key EphA2 downstream signaling molecules such as the p85 subunit 
of PI3 kinase and Vav guanine nucleotide exchange factors.  These uncoupling 
mutants permit the possibility to test whether recruitment of these proteins by EphA2 
receptor is critical for endothelial cell function in vivo.  As shown in Figures 22 and 
23, Y587/593 and Y734 are major sites for recruitment of Vav2/3 GEFs and p85, 
respectively, and the recruitment of both Vav proteins and p85 to the activated EphA2 
receptor is critical for ephrin-A1 induced endothelial cell migration and assembly.  It 
should be now feasible to screen for other putative EphA2 phosphotyrosine-
dependent interacting proteins such as Shc, SHP2, c-Cbl, and SLAP, or to use 
phosphopeptides as ligands in chromatography analysis to identify novel binding 
partners.  Moreover, EphA2 tyrosine phospho-specific monoclonal antibodies can be 
developed to facilitate the identification of downstream signaling events associated 
with EphA2 tyrosine phosphorylation. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 Ephrins and Eph receptors are key regulators of physiological and pathological 
processes in development and disease.  Expression of Eph receptors is often elevated 
in many types of malignant tumors, yet precise role of these molecules in cancer is 
not well understood.  The work in my thesis revealed for the first time a kinase-
dependent role of EphA2 receptor tyrosine kinase in promoting tumor malignancy.  I 
have shown that EphA2 functions in tumor promotion in part, through destabilization 
of cell-cell adhesion by a RhoA GTPase-dependent mechanism.  In addition to 
promoting tumor malignancy, EphA2 also plays critical roles in tumor angiogenesis.  
My work in vascular endothelial cells contributed to our understanding of how Eph 
receptor transduces signals in angiogenic responses and in tumor neovascularization.  
I found that phosphorylation of key tyrosine residues in the EphA2 receptor 
cytoplasmic domain recruits Vav family guanine nucleotide exchange factors and the 
p85 subunit of PI3 kinase, resulting in Rac1 GTPase activation, endothelial cell 
migration and assembly in vitro and incorporation of vascular endothelial cells into 
tumor vasculature in vivo.  Taken together, my thesis work showed that EphA2 
promotes tumor progression through both enhancing tumor malignancy and increase 
tumor angiogenesis.  
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EphA2: Oncogene or Tumor Suppressor? 
 Recently, there is a growing debate as to whether EphA2 is an oncogene or tumor 
suppressor, as there is evidence to support both roles.  Guo et al recently reported that 
loss of EphA2 increased susceptibility to skin carcinogenesis in EphA2 deficient gene 
trap mice treated with DMBA/TPA, a chemical carcinogen (161).  This would 
suggest that EphA2 functions as a tumor suppressor.  Another line of evidence is 
provided by work demonstrating EphB4 can also act as tumor suppressor.  Like 
EphA2, expression of EphB4 has been correlated with tumor malignancy in several 
cancer types.  Similar to EphA2, EphB4 is upregulated in cancer cells, but in cancer 
cells levels of phosphorylated EphB4 are reduced in comparison to normal tissue or 
cells.  Noren et al demonstrated that, in several different breast cancer cell lines, 
treatment with ephrinB2-Fc inhibited proliferation and increased apoptosis.  
Treatment with ephrinB2-Fc also inhibited cell motility and invasion (162).  These 
results would argue that the Eph receptor can function as a tumor suppressor. 
 There are published reports, however, demonstrating that EphA2 functions as an 
oncogene.  Zelinski et al reported that overexpression of EphA2 in MCF-10A cells 
was sufficient to transform those cells (30).  These transformed MCF-10A cells 
exhibited many properties consistent with those found in cancer cells.  EphA2 
overexpressing MCF-10A cells formed colonies on soft agar, and demonstrated 
increased cell migration.  In addition, inhibition of EphA2 by siRNA knockdown or 
receptor degradation reduced tumor volume and metastasis.  Brantley-Sieders et al 
reported that EphA2 deficiency decreased tumor burden in the MMTV-Neu mouse 
model of breast cancer (61).  In this model, overexpression of the oncogene, ErbB2, is 
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restricted to the breast epithelium.  These mice will form spontaneous mammary 
tumors within 3 months.  In MMTV-Neu mice also deficient in EphA2, tumor growth 
was significantly decreased.  Decreased tumor volume and metastasis was due, in 
part, to cooperative signaling between EphA2 and ErbB2.  It was demonstrated that 
EphA2 and ErbB2 could be co-immunoprecipitated.  Association of EphA2 and 
ErbB2 could enhance MAPK signaling (61).  My work suggests that in the context of 
breast cancer, EphA2 functions as an oncogene.  Inhibition of EphA2 signaling by 
overexpression of a dominant negative EphA2 mutant decreased tumor growth in 
vivo, while overexpression of EphA2 weakened cell-cell adhesion.  In my 
experimental system, overexpression of EphA2 in the MCF-10A cells did not appear 
to transform these cells.  When MCF-10A/EphA2 cells were cultured in a 3D-
Matrigel they behaved like parental MCF-10A cells, which is contrary to the results 
observed by Zelinski et al.  The discrepancy in results I believe is due to differences 
in the level of EphA2 overexpression.  I was not able to achieve EphA2 expression 
level comparable to those in the previous study, using the LZRS retroviral system.  
As described in Chapter IV, I demonstrated that high overexpression of EphA2 using 
an adenoviral vector resulted in more rapid destabilization of cell-cell adhesion, in 
comparison to the MCF-10A or MCF-10A/LZRS-EphA2 cells.  These data would 
argue that EphA2 acts as an oncogene. 
 To reconcile the dual roles of Eph receptors in tumor promotion and tumor 
suppression, we proposed a working model (Fig 26).  Under physiologic conditions, 
epithelial cells form cell-cell junctions, permitting ephrins to interact with Eph 
receptors in trans on adjacent cells (28, 163).  Ligand stimulation inhibits the 
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activation of Ras-MAPK pathway, the RhoA GTPase, and the function of the adaptor 
Crk through Abl kinase activity, keeping cells quiescent and non-invasive (41, 42).  
Upon tumor initiation, Eph receptor expression is up-regulated by oncogenic 
signaling pathways such as the Ras-MAPK pathway or the Wnt-β-catenin pathway, 
whereas their ephrin ligands are often downregulated (42, 164).  Cross talk between 
elevated Eph receptors and other oncogenes, such as the ErbB family of receptor 
tyrosine kinases (61, 165) leads to enhanced cell proliferation and tumorigenesis, 
presumably independently of ephrin stimulation.   Thus, ligand-dependent Eph 
receptor signaling functions in tumor suppression, whereas ligand-independent Eph 
receptor activities appear to promote tumor progression.  It remains to be determined 
whether the differences in signaling in the above two scenarios are achieved by 
differential receptor phosphorylation or mediated through phosphorylation-
independent mechanisms, such as signaling through the SAM domain or PDZ binding 
motif at the cytoplasmic domain. The precise role of Eph receptor kinase activity also 
remains to be determined. 
 
EphA2 phosphorylation and signaling 
 Biochemical anaylsis of the phosphorylated tyrosines on EphA2 only identified 
three tyrosine residues that were phosphorylated on EphA2 by both mass 
spectrometry and 2D-TLC coupled with phosphopeptide mapping.  Characterization 
of EphA4, EphB2, and EphB5 using in vitro and in vivo labeling revealed tyrosines in 
similar positions were also phosphorylated (154, 156).  They identified the 
juxtamembrane tyrosines and the corresponding tyrosine in the activation loop, these 
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Figure 26.  A working model for the dual roles of Eph receptors in tumor promotion 
and tumor suppression.  In normal cells, engagement of Eph receptors with ephrins on 
adjacent cells in trans induces receptor forward signaling, leading to inhibition of 
Ras/MAPK activity or RhoA GTPase.  Reverse signaling through ephrin-B stabilizes 
cell-cell adhesion.  In tumor cells, disruption of cell-cell junctions inhibits Eph 
receptor interaction with endogenous ephrins in trans.  In addition, some tumor cells 
have low ephrin levels. Elevated Eph receptors cross talk with other receptor tyrosine 
kinases can result in increased activity of the Ras-MAPK pathway, the RhoA 
GTPase, and enhanced tumor malignancy. 
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are Y587, Y593, and Y771 on EphA2.  However, these analyses also identified 
several other tyrosines, predominantly found in the kinase domain.  I believe the lack 
of sensitivity of our assays maybe responsible for the differences.  To gain better 
insight into EphA2 phosphorylation, we would need to perform similar experiments 
using in vivo labeling of EphA2 phosphorylation as opposed to the in vitro kinase 
assay.  I would predict that many more of the 15 possible tyrosine residues found 
within the cytoplasmic domain of EphA2 would be phosphorylated.   
 To date, there have been numerous proteins that have been demonstrated to 
interact with EphA2, generally mediated by SH2/PTP domains.  In my work, I have 
identified four proteins that interact with EphA2 and mapped their association on 
EphA2.  This work has generated an extensive library of EphA2 tyrosine mutants.  As 
a result of my work, it is now be possible to map interactions with other proteins, e.g. 
LMW-PTP, p120 RasGAP, Src family of kinases, adaptor proteins (such as Grb2 and 
Nck), and other Rho GEFs (such as ephexin and Vsm-RhoGEF) to obtain a greater 
understanding of downstream signaling events.   
It is still unclear what signaling pathways are active due to EphA2 upregulation.  
In the context of cancer, there appears to be several pathways that are commonly 
affected by EphA2 activation.  It has been reported in many systems that upregulation 
of EphA2 signaling affects cell adhesion, cell migration, and cell proliferation.  One 
pathway that consistently is shown to be upregulated by EphA2 signaling is the Rho 
family of GTPases.  EphA2 signaling functions through several different pathways to 
alter Rho activation.  Zhuang et al demonstrated that SHIP2 association with EphA2 
activated Rac1 through phosphoinositide 3-kinase (58).  Parri et al reported that 
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activation of EphA2 increased RhoA activation by increasing Src activity and 
subsequent FAK phosphorylation (72).  These findings are consistent with my work.  
In 4T1 cells, I observed a decrease in RhoA activation when EphA2 signaling was 
inhibited by overexpression of a dominant negative EphA2 mutant, while 
overexpression of EphA2 in MCF-10A cells increased RhoA activation.  Another 
pathway that is commonly affected by EphA2 signaling is the MAPK pathway.  
Interestingly, Ras-Raf signaling was reported to upregulate EphA2 expression 
through activation of the MAPK pathway (42, 166).  Conversely, EphA2 has been 
shown to affect Ras-Raf signaling as well.  EphA2 can inhibit MAPK activation.  
Miao et al reported that stimulation of PC-3 cells with ephrinA1 could dramatically 
decrease levels of activated Erk (41).  However, EphA2 can also activate the MAPK 
pathway.  Pratt et al reported that stimulation of EphA2 with ephrinA1-Fc increased 
Erk activation and cell proliferation in prostate cancer cells (60).  EphA2 signaling 
can also affect cell adhesion.  As mentioned previously, Parri et al reported that 
EphA2 signaling can increase FAK phosphorylation through Src to cause cell 
retraction in prostate cancer cells (72).  Miao et al also reported that EphA2 signaling 
can affect the phosphorylation status of FAK to decrease cell adhesion.  Miao et al 
demonstrated that in the absence of ephrinA1 stimulation, FAK and EphA2 can 
associate.  However, in the presence of ephrinA1 binding to EphA2, FAK becomes 
dissociated from EphA2 and is dephosphorylated by a tyrosine phosphatase (41).  In 
my work, I did not observe any difference in levels of FAK phosphorylation. Similar 
to Parri et al, I did observe cell retraction with ephrinA1-FC stimulation of MCF-10A 
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cells that overexpressed EphA2.  It is currently unclear how there can be two 
opposing results in response to EphA2 signaling. 
 There is a growing body of work that has demonstrated Eph receptors can interact 
with other RTKs.  Larsen et al reported that EphA2 and EGFR can be co-
immunoprecipitated (165).  The interaction between EGFR and EphA2 increased cell 
motility.  Warner et al recently reported using an in vitro systematic analysis of 
EphA4 peptide substrates that EphA4 can phosphorylate EGFR (167).  Brantley-
Sieders et al demonstrated that EphA2 can physically interact with ErbB2 (61).  
EphA2 interaction with ErbB2 could enhance MAPK activation, while EphA2 
deficiency could decrease tumor size in the MMTV-Neu transgenic mice (61).  These 
results would suggest that EphA2 can phosphorylate other RTKs and other RTKs can 
phosphorylate EphA2 to facilitate different signaling events.  It will now be possible 
to investigate which tyrosines can be phosphorylated by other RTKs and what 
signaling pathways these interactions activate. 
 EphA2 activation is dependent upon ligand binding of the receptor and clustering 
of the receptor.  Recent work on the ephrins has demonstrated that the ephrin ligands 
can be cleaved by presenilin and metalloproteases.  There have been two proposed 
mechanisms for termination of Eph forward signaling.  Ligand engagement with the 
Eph receptor is thought to cause internalization of the receptor/ligand complex.  
Another possible mechanism is proteolysis of the ephrin ligand by metalloproteases.  
Georgakopoulosa et al reported that ephrinB2 can be cleaved by metalloproteases to 
produce a 14 kd fragment (168).  Similarly, ephrinA5 and ephrinA2 can be cleaved 
by ADAM10.  This cleavage occurred in a trans manner, occurring when ephrin 
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expressing cells engage and bind to the Eph receptor(169).  In the original studies on 
ephrinA1, Bartley et al demonstrated that soluble monomeric ephrinA1 was able to 
induce EphA2 phosphorylation (170).  These studies would suggest that the ephrins 
can be cleaved and exist as soluble factors.  It is unclear what ramification this would 
have for Eph receptor signaling, as EphA2 activation is generally mediated by 
receptor clustering and Eph phosphorylation.  It is clear that Eph signaling is quite 
complicated.  Eph receptors can signal through kinase dependent and kinase 
independent, ligand dependent and ligand independent pathways, and they can 
cooperatively associate with other receptor tyrosine kinases to facilitate different 
signaling cascades.  In my work, I addressed the contribution of kinase dependent 
EphA2 signaling in breast cancer cells.  EphA2 activation promotes tumor 
progression.  4T1 mammary carcinoma cells express high levels of EphA2, and I 
reported that EphA2 phosphorylation and activation was dependent on cell density or 
cell-cell contact.  Inhibition of EphA2 signaling by overexpression of an EphA2 
truncation mutant decreased tumor volume and metastasis.  In MCF-10A cells, 
overexpression of EphA2 weakened cell-cell adhesion.  It would be interestingly to 
do a comparative study on the many different forms of Eph signaling and whether 
different tyrosines are phosphorylated in response to the different forms of Eph 
signaling.  This point is addressed further in the perspectives section. 
 
Therapeutics 
 An ultimate goal of most biomedical research is to identify novel information that 
can be utilized to develop therapies targeting certain molecules in different diseases.  
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In the field of Eph research, there have been several studies that have show promise 
for targeting EphA2 in relation to cancer therapy.  There are wide array of strategies 
that have been used including monoclonal antibody conjugates, ligand based 
cytotoxins, siRNA, antangonistic peptides, and small molecule inhibitors.  Wykosky 
et al reported that a portion of ephrinA1 ligand conjugated with a modified bacterial 
toxin was a potent inhibitor of glioblastoma multiforme cells that overexpressed 
EphA2 (171).  Several groups have shown the effectiveness of using siRNA methods 
to inhibit tumor progression.  Landen et al demonstrated that knockdown of EphA2 
could dramatically reduce tumor growth in a mouse model of ovarian cancer (172).  
Consistent with these findings, Duxbury et al also showed that knockdown of EphA2 
in prostate cancers could do the same (38).  These results are consistent with my 
findings in 4T1 mammary adenocarcinoma cells, as inhibition of EphA2 exhibited a 
statistically significant reduction in tumor growth and metastasis.  Chencik et al and 
Koolpe et al have demonstrated that an antagonistic peptide for ephrinB2 could 
inhibit endothelial cell function (122, 173).  These findings would suggest that 
therapeutic strategies targeting Eph receptors are promising for both tumor cells and 
tumor vasculature. 
 A growing area of research involves the interaction of Eph receptors with other 
families of receptors.  Current work in this area has demonstrated that Eph receptors 
can potentiate signaling from other RTKs, including EGFR family of receptors, FGF 
receptors, or HGF signaling (61, 128, 165, 167).  Eph receptor can also coordinate 
signaling with chemokine receptors and with integrin signaling .  Signaling from 
these proteins has also been reported to be important in the context of cancer.  This 
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area of research holds great promise for novel treatment in cancer therapeutics.  It 
would be possible to use combinatorial therapy, where treatment would target 
multiple proteins or pathways, to produce greater efficacy in cancer treatment.  
However, the mechanisms by which the Eph receptors could crosstalk with other 
receptors or proteins are not well understood.  It will be necessary to dissect how Eph 
receptor signaling can influence other receptor signaling and how other receptors can 
influence Eph receptor signaling in cancer cells.  More research will have to be done 
to address this, but this will be of great importance in terms of cancer treatment. 
 
Perspective 
 Since the discovery of the first Eph receptor some 20 years ago, there has been 
tremendous progress in understanding this family of receptor tyrosine kinases.  My 
work has demonstrated that EphA2 signaling is important in tumor progression.  
However, it is evident that there are still many unanswered questions in the field.  
Firstly, how can EphA2 function as both a tumor suppressor and oncogene?  Studies 
on EphA2 deficient mice showed that these mice exhibited no overt phenotype under 
physiological conditions.  However, when the mice were challenged with disease the 
results were contradictory.  Guo et al demonstrated that EphA2 deficiency in a gene 
trap model promoted skin carcinogenesis (161).  Brantley-Sieders et al reported that 
EphA2 deficiency in a conventional knockout decreased tumor progression in the 
MMTV-Neu mouse model of breast cancer.  Although in this work, it was reported 
that the role of EphA2 in breast cancer maybe dependent on the context of the tumors, 
as EphA2 deficiency did not affect tumor volume in the MMTV-PyV-MT mouse 
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model of breast cancer (61).  One approach to address the dual functions of EphA2 in 
cancer would be to look at how in vivo overexpression of EphA2 can affect tumor 
formation and progression.  It would be advantageous to generate an EphA2 
transgenic mouse model and examine how EphA2 overexpression affects tumor onset 
and progression.  We would predict that if EphA2 functioned as a tumor suppressor in 
skin cancer, then treatment of these EphA2 transgenic mice with chemical 
carcinogens, as described Guo et al, would result in a decrease incidence of cancer.  It 
is unclear whether overexpression of only EphA2 is sufficient to induce tumor 
formation.  It is possible that the ephrinA ligands also play a role in this.  It has been 
reported that EphA2 and ephrinA1 expression are inversely related.  In early cancer 
cells, ephrinA1 levels are elevated but ephrinA1 expression is reduced in cells with a 
high degree of malignancy.  EphA2 levels, on the other hand, are lower in early stage 
tumors than in later stage tumors.  To investigate the role of ephrin/Eph in tumor 
initiation, we will need to dissect the mechanism of ligand mediated EphA2 signaling. 
 Eph receptor signaling is very complex.  Eph receptors can signal through a 
ligand dependent and independent mechanisms, as well as kinase dependent and 
independent processes.  It is also possible to have reverse signaling though the ephrin 
ligands.  To investigate ligand dependent versus independent signaling, it would be 
interesting to see what difference in tyrosine phosphorylation there is between the two 
groups.  Are different tyrosine residues phosphorylated on EphA2 in the presence of 
ligand versus absence of ligand?  Mass spectrometry analysis could be used to 
address this.  A complementary approach would be to identify different signaling 
proteins that are upregulated or downregulated in the presence or absence of ligand.  
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2D-DIGE is a powerful tool that can address this question.  The combination of these 
approaches would identify tyrosine phosphorylation sites that are relevant to ligand 
activation and signaling pathways that are ligand dependent and ones that are 
independent.  This experiment would be vital in reconciling whether EphA2 is a 
tumor suppressor or oncogene in cancer.  According to our model, we would expect 
that proteins involved in Rho and MAPK signaling pathways would be 
downregulated in the presence of ephrinA ligand stimulation, while in the absence of 
ligand these pathways would be upregulated.  It would also be possible to address the 
differences in proteins that interact with EphA2 in a ligand dependent and ligand 
independent fashion.  We currently have a large panel of EphA2 tyrosine to 
phenylalanine mutants that could be used to address and verify the results seen from 
the proteomic analysis of EphA2 signaling with and without ligand treatment. 
This report and other studies on the Eph receptor family have shown us that 
we are at an exciting time in this area of research.  There has been tremendous 
progress, but many questions remain unanswered.  There is great potential that future 
work will lead to effective new therapies for cancer treatment.  Therapeutic strategies 
specifically targeting Eph receptors will not only target cancer cells but also tumor 
specific stromal cells, including tumor endothelium.  There are still many unresolved 
dilemmas that will need to be addressed, but this work has provided a step forward to 
achieving this. 
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